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ABSTRACT 
A growing interest has been recently devoted to the role of intracellular Ca2+ stores in 
brain ischemia. For instance, disturbances of Ca2+ content in the endoplasmic reticulum (ER), 
the main intracellular Ca2+ store, have been reported as one of the main mechanisms underlying 
this neurological disease. Interestingly, lysosomes are emerging as other important Ca2+-storing 
organelles, cooperating with the ER in the handling of intracellular Ca2+ concentration ([Ca2+]i). 
One of the main regulators of lysosomal Ca2+ homeostasis is represented by Transient Receptor 
Potential Mucolipin 1 (TRPML1), a non-selective cation channel releasing lysosomal Ca2+ into 
the cytosol.  
In this study we investigated the role of ER/lysosome Ca2+ coupling and the contribution 
of TRPML1 in brain ischemia. Our results showed that under physiological conditions 
TRPML1 activation induced by its specific agonist ML-SA1 or by lysosomal v-ATPase 
inhibitor bafilomycin A1 significantly increased [Ca2+]i in cortical neurons. ML-SA1-induced 
Ca2+ leak from lysosomes strongly reduced ER Ca2+ content, whereas the TRPML1 inhibitor 
trans-Ned19 or channel knocking down increased ER Ca2+ levels. However, this interplay was 
disrupted under hypoxic conditions produced by exposing cortical neurons to oxygen and 
glucose deprivation (OGD) followed by reoxygenation (Rx). Indeed, during OGD/Rx both ER 
and lysosomal Ca2+ levels were significantly impaired. Interestingly, the administration of 
trans-Ned19 during the reoxygenation phase prevented dysfunctional lysosomal Ca2+ 
homeostasis and neuronal death. In consideration of the role played by lysosomes in autophagy 
regulation, we showed that trans-Ned19 hampered the autophagic flux during hypoxia thus 
protecting neurons. Moreover, we found that in ischemic rats subjected to the transient 
occlusion of the middle cerebral artery (tMCAO) the intracerebroventricular (icv) 
administration of this drug at the onset of reperfusion was able to reduce the brain ischemic 
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volume, ameliorated the general and focal deficits, and promoted a protective blockade of the 
autophagic flux.  
Collectively, the results presented in my PhD thesis demonstrate the detrimental role of 
TRPML1 dysfunction in the neurodegeneration associated to brain ischemia, thus identifying a 
novel potential therapeutic target that could be pharmacologically modulated, together with 
other relevant mechanisms, to induce neuroprotection. 
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1. INTRODUCTION 
1.1 Lysosome: the cell’s recycling centre 
Lysosomes are membrane-enclosed intracellular organelles, identified and 
characterized by the Belgian cytologist and biochemist Christian de Duve in 1955 using a cell 
fractionation technique (de Duve C. et al., 1955). The term “lysosomes” originated from the 
Greek words λύσις/lysis, which means dissolution or destruction, and σώμα/soma, which means 
body, thus reflecting the ability of these organelles to degrade specific substrates within the 
cell. Lysosomes can be found in almost all animal cells with the exception of very few, highly 
specialized cell types, including red blood cells (Allison A. et al., 1967). Each mammalian cell 
normally contains several hundreds of lysosomes, which comprise up to 5% of the intracellular 
volume. They are heterogeneous in size and morphology; indeed, their canonical diameter 
ranges from 50 nm to 500 nm and, although they often show a globular shape, sometimes they 
can be tubular. Moreover, they often contain electron-dense deposits within their lumen and 
sometimes multilamellar membrane whorls. Lysosomal size and number can vary in cells 
following different pathophysiological stimuli. For instance, the accumulation of undigested 
materials within their lumen leads to a dramatic increase in both their size and number. By 
contrast, upon nutrient starvation, lysosomal number is drastically reduced to <50 per cell, and 
their size is increased up to 1500 nm as a result of membrane fusion events (Alberts B. et al., 
1994; Luzio J.P. et al., 2007; Saftig P. and Klumperman J., 2009; Appelqvist H. et al., 2013; 
Xu H. and Ren D., 2015).   
Lysosomes are characterized by an acidic lumen (pH ~4.5) and contain more than 60 
different soluble hydrolytic enzymes, including proteases, glycosidases, nucleases, lipases, 
sulfatases, and phosphatases. Each kind of hydrolase degrades a specific target substrate at 
acidic pH, and, collectively, these enzymes ensure the degradation of all types of 
macromolecules. The breakdown products derived from the degradation process are usually 
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exported to the cytoplasm, where they become available for metabolic reuse (Bainton D.F., 
1981; Luzio J.P. et al., 2007; Appelqvist H. et al., 2013). The best-characterized class of 
lysosomal hydrolases is represented by the cathepsin family of proteases. In humans several 
members of cathepsin family have been identified. They have been classified into three distinct 
groups, based on the amino acid found in their active site: serine (cathepsin A, and G), cysteine 
(cathepsin B, C, F, H, K, L, O, S, V, W, and X), and aspartic cathepsins (cathepsin D, and E). 
The aspartic cathepsin D and some of the cysteine cathepsins (including cathepsins B, C, H, 
and L) are ubiquitous and among the most abundant lysosomal proteases (Appelqvist H. et al., 
2013). 
To protect the cell from an unwanted degradation, lysosomes are limited by a 7-10 nm 
single phospholipid-bilayer, poor in cholesterol and extremely rich in carbohydrates (Schulze 
H. et al., 2009; Saftig P. et al., 2010). The high carbohydrate content is a unique feature of 
lysosomal membrane and is due to the presence of several integral proteins that are heavily 
glycosylated within their luminal domains, and hence resist digestion. The most abundant 
lysosomal glycoproteins include LAMP1 (lysosomal associated membrane protein 1), LAMP2 
(lysosomal associated membrane protein 2), LIMP1 (lysosomal integral membrane protein 
1)/CD63, and LIMP2 (lysosomal integral membrane protein 2). These heavily glycosylated 
proteins create a continuous and thick (~8 nm) glycocalyx on the inner side of lysosomal 
membrane, which protects the cell from the luminal acidic environment and from the action of 
acidic hydrolases (Neiss W.F., 1984; Eskelinen E.L. et al., 2003; Saftig P. et al., 2010). 
The acidic pH required for the activation of lysosomal hydrolases and for the regulation 
of many other lysosomal functions is generated and maintained by the proton-pumping vacuolar 
H+-ATPase (or v-ATPase), a transmembrane multimeric complex which is present and active 
in all types of eukaryotic cells. It uses energy from ATP hydrolysis to actively transport protons, 
against their electrochemical gradient, from the cytoplasm to the lysosomal lumen; in particular, 
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two protons are translocated per ATP hydrolyzed (Ohkuma S., et al., 1982; Finbow M.E. and 
Harrison M.A., 1997; Mindell J.A., 2012).  
Materials destined for degradation can reach lysosomes through two main pathways: 
extracellular materials are taken up from outside the cell and transported to lysosomes by the 
endocytic pathway, whereas intracellular components are delivered to lysosomal compartments 
via the autophagic pathway (de Duve C., 2005).  
 
1.1.1 The endocytic pathway 
Endocytosis is a process mediating the internalization of fluid, external solutes, 
macromolecules, plasma membrane (PM) components, and particles by the invagination of the 
PM and the subsequent formation of vesicles and vacuoles through membrane fission events. 
In metazoan cells, endocytosed cargo includes several biomaterials, such as nutrients and their 
carriers, receptor-ligand complexes, fluid, solutes, lipids, membrane proteins, extracellular-
matrix components, cell-debris, and pathogens (including viruses, bacteria, parasites, and 
toxins) (Huotari J. and Helenius A., 2011; Grimm C. et al., 2017).  
Endocytosis starts with the formation of endocytic vesicles budding from the PM that 
mediate the entry of cargoes within the cell. Endocytic vesicles then fuse with early endosomes 
(EEs), the main sorting station in the endocytic pathway (Huotari J. and Helenius A., 2011; 
Reggiori F. and Klumperman J., 2016). The majority of cargoes delivered during endocytosis, 
including most receptors, is recycled back to PM through the recycling endosomes (REs). By 
contrast, the biomaterials destined for degradation are retained in the EEs and, through a multi-
step process, reach the lysosomes for digestion (Appelqvist H. et al., 2013). EEs have a complex 
structure consisting of a vacuolar body with an approximative diameter of 100-500 nm that is 
associated with cytosolic-facing tubular membrane extensions (Cullen P.J. and Steinberg F., 
2018), and are characterized by a luminal pH of 5.9-6.8 (Reggiori F. and Klumperman J., 2016). 
Within EEs, materials addressed to degradation are incorporated into intraluminal vesicles 
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(ILVs) which are formed from the endosomal limiting membrane and are essential for efficient 
cargo sorting. Along the endocytic pathway, EEs, through a process involving exchange of 
materials and multiple membrane fusion events, are then converted into late endosomes (LEs). 
LEs are spherical organelles with an approximative diameter of 250-1000 nm and a pH of ~5-
6 (Appelqvist H. et al., 2013; Reggiori F. and Klumperman J., 2016). Due to the high content 
of ILVs, they are often referred to as “multivesicular bodies” (MVBs). Via the generation of 
ILVs, lipids and membranes are delivered to lysosomes in a form that is easily accessible to 
lysosomal hydrolases for degradation (Appelqvist H. et al., 2013). Once matured, the LE fuses 
with a lysosome to form an intermediate fusion-hybrid organelle, the endo-lysosome (EL), 
which mediates the degradation of the incorporated cargoes. Subsequently lysosomes are 
regenerated from the fusion-hybrid organelles via a process known as lysosome biogenesis 
(Luzio J.P. et al., 2009; Xu H. and Ren D., 2015).   
 
 
 
 
 
 
 
 
 
 
Fig.1 - The endosome/lysosome system. The primary endocytic vesicles budding from the PM deliver 
their cargo to the EEs in the peripheral cytoplasm and fuse with them. However, most of cargo is 
recycled back to PM through the recycling endosomes. After a period of 8-15 minutes EEs are converted 
in LEs. The nascent LE carries a selected subset of endocytosed cargo from EE, and newly synthesized 
lysosomal hydrolases and membrane components derived from the secretory pathway. Following a 
maturation process, the LE fuses with a lysosome, generating a transient hybrid organelle named endo-
lysosome, in which active degradation of cargoes takes place (modified from Huotari J. and Helenius 
A., 2011).  
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The maturation process from EE to lysosome takes ~40 minutes. During this time, the 
vesicle undergoes a multitude of changes, including exchange of membrane components, 
movement to the perinuclear area, formation of ILVs, decrease in luminal pH, acquisition of 
lysosomal proteins, and changes in morphology (Appelqvist H. et al., 2013). In addition, during 
endosome maturation, there is a continuously ongoing trafficking between endosomes and 
trans-Golgi network (TGN), which occurs at the level of both EEs and maturing LEs, and 
probably also after fusion of LEs with lysosomes (Huotari J. and Helenius A., 2011). This 
process allows the delivery of newly synthesized enzymes and proteins from the TGN to the 
appropriate endo-lysosomal compartments. Because of the continuous exchange of content 
between the intermediate compartments participating in the endocytic pathway, it is difficult to 
identify markers that specifically label a single organelle. Nevertheless, early endosomal 
antigen 1 (EEA1) and Rab5 are commonly used as markers of EEs. LEs and lysosomes show 
an overlapping molecular content, including LAMP proteins, and acidic hydrolases (Appelqvist 
H. et al., 2013). However, lysosomes are characterized by the lack of mannose-6-phosphate 
receptors (M6PR), a criterion generally used to distinguish these compartments from LEs 
(Brown W.J. et al., 1986; Appelqvist H. et al., 2013).  
At present, the regulation mechanisms of the endocytic pathway are not yet fully 
understood. However, several proteins have been found to participate in the regulation of 
endocytosis and intracellular trafficking, e.g. coat proteins, adaptors, retrieval proteins, scission 
proteins, Rab GTPases, and soluble N-ethylmaleimide sensitive factor attachment protein 
receptor (SNARE) proteins (Grimm C. et al., 2017). 
   
1.1.2 The autophagic pathway 
Autophagy is an evolutionarily conserved cellular process through which cytoplasmic 
materials, such as proteins or even complete organelles, are directed to lysosomes for 
degradation. This process allows the clearance of protein aggregates, long-lived proteins, 
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misfolded proteins and dysfunctional and damaged organelles, and ensures the recycling of 
their constituents (Ravikumar B. et al., 2010; La Rovere R.M.L. et al., 2016). In mammals 
autophagy occurs under basal conditions and is implicated in the maintenance of normal cellular 
homeostasis (Ravikumar B. et al., 2010). However, the process can be stimulated by several 
physiological and pathological conditions, including starvation, hypoxia, reactive oxygen 
species (ROS) production, pathogen infection, various diseases, or by treatment with 
pharmacological agents like rapamycin and torin-1. Under these conditions, the activation of 
autophagy allows cells to overcome the stress, thus promoting cell survival. However, an 
impairment in the autophagic process can contribute to the pathogenesis of several human 
diseases, including neurodegenerative disorders, cancer and infectious diseases (Ravikumar B. 
et al., 2010; La Rovere R.M.L. et al., 2016). In mammalian cells three major subtypes of 
autophagy have been described, based on the mechanism by which substrates reach the 
lysosomal lumen: chaperone-mediated autophagy (CMA), microautophagy, and 
macroautophagy. Only soluble proteins, but not complete organelles, can be delivered to 
lysosomes via CMA (Cuervo A.M., 2010), whereas micro- and macroautophagy participate in 
the degradation of both proteins and organelles (Yang Z. and Klionsky D.J., 2009). In more 
detail, CMA is characterized by the translocation of cytosolic proteins with the pentapeptide 
KFERQ motif into the lysosomal lumen directly across lysosomal membrane. In this process, 
protein import is directly mediated by the lysosomal-associated membrane protein type 2A 
(LAMP2A) translocation complex (Cuervo A.M., 2010; La Rovere R.M.L. et al., 2016). 
Microautophagy is a constitutive and sometimes selective process by which whole portions of 
the cytoplasm are engulfed by direct invagination of lysosomal membrane into tubulovesicular 
structures (Ravikumar B. et al., 2010; Wong W. and Cuervo A.M., 2010; Nixon R.A. and Yang 
D.S., 2012). Macroautophagy, hereafter referred to as autophagy, is the most extensively 
studied and the best characterized form of autophagy. During this process, a portion of the 
cytoplasm, including soluble materials and organelles, is sequestered within a de novo-formed 
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double-membraned structure, the phagophore (also called the isolation membrane). After 
elongation, phagophore closes upon itself to form a discrete double-membrane autophagic 
vesicle, the autophagosome, which entraps sequestered cytosolic cargoes. Subsequently, via 
cytoskeleton-dependent motion, autophagosome engages and fuses with lysosome in a calcium 
(Ca2+)-dependent manner, thus forming a fusion-hybrid organelle called autolysosome. Within 
the autolysosome, lysosomal enzymes degrade cargoes and the resulting macromolecules are 
transported back to the cytosol for recycling (Yang Z. and Klionsky D.J., 2009; Burman C. and 
Ktistakis N.T., 2010; Appelqvist H. et al., 2013; Carlsson S.R. and Simonsen A., 2015; La 
Rovere R.M.L. et al., 2016; Bootman M.D. et al., 2018). When the autophagic process is 
completed, through lysosome biogenesis, lysosomes are reformed from the fusion-hybrid 
organelles (Xu H. and Ren D., 2015). 
For a long time, autophagy has been considered a non-selective degradative pathway, 
involved in the degradation of randomly-sequestered cytoplasmic constituents. However, in the 
last years autophagy has been revealed as a more selective process, leading to the degradation 
of specific subsets of cellular components. Several targets of selective autophagy have been 
identified, including aggregated proteins (aggrephagy), lipids (lipophagy), mitochondria 
(mitophagy), peroxisomes (pexophagy), ribosomes (ribophagy), endoplasmic reticulum 
(reticulophagy, or ER-phagy) and pathogens (xenophagy) (Ravikumar B. et al., 2010; Stolz A. 
et al., 2014; Klionsky D.J. et al., 2016).  
Autophagy is a highly dynamic multi-step process regulated by approximately 30 
autophagy-related proteins (Atg), that coordinate the different steps of the process (initiation, 
elongation, maturation, autophagosome-lysosome fusion) (La Rovere R.M.L. et al., 2016). 
Phagophore formation is primarily induced by the assembly and activation of a multiprotein 
complex, the ULK1 complex, containing ULK1 (unc-51-like kinase 1), Atg13, FIP200, and 
Atg101. This complex can be regulated by two proteins with kinase activity, the cell growth 
regulator mTOR (mammalian target of the rapamycin), and the cell energy sensor AMPK 
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(AMP-activated protein kinase) (Nixon R.A., 2013). Under starvation, AMPK, which responds 
to reduced cytosolic ATP levels and consequent AMP accumulation, directly activates ULK1 
through phosphorylation of Ser317 and Ser777, thus promoting autophagy. By contrast, under 
normal conditions, high mTOR activity prevents ULK1 activation by phosphorylating this 
protein in Ser757 and disrupting the interaction between ULK1 and AMPK (Kim J. et al., 
2011). Upon AMPK-mediated phosphorylation, ULK1 complex, in turn, phosphorylates 
AMBRA (activating molecule in beclin1-regulated autophagy), a component of the autophagy-
specific class III phosphatidylinositol 3-kinase (PI(3)K) complex, containing Vps34 (vacuolar 
protein sorting 34), Vps15 (vacuolar protein sorting 15), beclin 1, and Atg14. This event 
promotes the translocation of PI(3)K complex from cytoskeleton to the phagophore, thus 
initiating phagophore elongation (Nixon R.A., 2013). Moreover, the phosphorylation of beclin 
1 stimulates the local production of phosphatidylinositol 3-phosphate (PI(3)P) by Vps34 
activity (Stolz A. et al., 2014). PI(3)P specifically binds to the early autophagic effector proteins 
WIPI1/2 (WD repeat domain phosphoinositide-interacting protein 1/2) and Atg21 (Nixon R.A., 
2013; Stolz A. et al., 2014). Another protein essential in this step of autophagy is Atg9, which 
together with Atg2 and members of the WIPI protein family forms another functional cluster. 
Atg9 has been reported to localize to different compartments, including recycling endosomes, 
late endosomes, TGN, and plasma membrane, and dynamically associates with the phagophore 
(Reggiori F. and Klumperman J., 2016). Although the precise function of Atg9 is still unknown, 
it has been proposed that it could cycle between endosomes, TGN and the phagophore, carrying 
some lipid components essential for membrane expansion (Nixon R.A., 2013; Reggiori F. and 
Klumperman J., 2016). Two ubiquitination-like reactions regulate further elongation and 
closure of the phagophore. In the first reaction, Atg5 and Atg12 are conjugated to each other in 
the presence of two additional Atg proteins (Atg7 and Atg10), and subsequently associate with 
Atg16L. The fully formed complex (containing Atg5, Atg12, and Atg16L) recruits the second 
ubiquitination-like conjugation system to the phagophore, inducing the conjugation of 
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phosphatidylethanolamine (PE), a lipid constituent of membranes, to members of microtubule-
associated protein light chain 3 (MAP-LC3, hereafter referred to as LC3) protein family (LC3A, 
LC3B, LC3C). In detail, newly synthesized LC3 (pro-LC3) is post-translationally processed at 
its C-terminus by the cysteine protease Atg4 to generate the cytosolic non-lipidated form of 
LC3 (LC3-I). Upon autophagy induction, LC3-I is conjugated to PE on both the inner and outer 
membrane of the phagophore through the action of Atg7 and Atg5-Atg12-Atg16L complex. 
The resulting lipidated form of LC3 (LC3-II), together with the Atg5-Atg12-Atg16L complex, 
is thought to form a protein coat that drives the formation of autophagosomes, possibly by 
deforming membranes (Reggiori F. and Klumperman J., 2016).  
 
 
 
 
 
 
 
 
 
 
Fig.2 - Autophagy induction and autophagosome biogenesis. Schematic depicting the molecular 
components and protein complexes involved in the induction of autophagy and in the subsequent 
formation of the autophagosome starting from the phagophore. The steps of the process indicated in red 
are known to be affected in some neurodegenerative diseases (modified from Nixon R.A., 2013).   
 
Another important protein in the autophagic process is SQSTM1/p62, a scaffolding 
protein that can be considered a linker between autophagy and polyubiquitylated substrates. 
Indeed, it acts as an autophagy receptor shuttling the polyubiquitylated proteins bound to its 
ubiquitin associated domain (UBA) to the autophagic machinery, by directly interacting with 
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LC3-II (Liebl M.P. and Hoppe T., 2016). Interestingly, p62 itself is also a substrate of 
autophagy: indeed, p62 and p62-bound polyubiquitylated proteins are incorporated into the 
complete autophagosomes and degraded within autolysosomes, thus serving as an index of 
autophagic degradation. Since basal autophagy keeps p62 at relatively low levels, an increase 
in its expression is the result of autophagy inhibition (Klionsky D.J. et al., 2016; Liebl M.P. 
and Hoppe T., 2016; Yin Y. et al., 2017). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.3 - p62 links polyubiquitylated substrates to autophagy. (A) Under conditions of productive 
autophagy, p62 shuttles polyubiquitylated substrates for autophagosomal degradation and is itself a 
substrate of autophagy. (B) When autophagy is impaired, polyubiquitylated substrates accumulate and 
p62 is not degraded by the autophagic machinery (modified from Liebl M.P. and Hoppe T., 2016). 
 
Given that autophagy is a highly dynamic process, the term “autophagic flux” is 
generally used to refer to the whole process of cargo moving through the autophagic system, 
16 
 
from phagophore to autophagosome formation, including cargo delivery to lysosomes and 
subsequent cargo breakdown (Klionsky D.J. et al., 2016; Yin Y. et al., 2017). In this case the 
process may be referred to as “productive” or “complete” autophagy (Klionsky D.J. et al., 
2016). However, an accumulation of autophagosomes could reflect a reduction in 
autophagosome turnover, due, for example, to a block in fusion with lysosomes or to an 
impairment in the digestive functions of lysosomes, which leads to an inefficient cargo 
degradation once fusion has occurred. In this scenario, although autophagy is induced, there is 
no or limited autophagic flux. In these conditions, the block in the autophagic flux is 
accompanied by an increase in the expression levels of some autophagic markers, including 
p62 and LC3-II (Klionsky D.J. et al., 2016). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.4 - Normal versus defective autophagic flux. (A) Autophagy starts with the formation of the 
phagophore, which subsequently expands to form the autophagosome. To ensure a normal autophagic 
flux, the completion of the process requires the fusion of the autophagosomes with lysosomes to form 
autolysosomes, in which cargoes are degraded by lysosomal enzymes. (B) A defect in autophagosomes 
turnover, due to a block in fusion with lysosomes or to an impairment in lysosomal degradation, leads 
to a block in the autophagic flux, which is accompanied by an increased number of autophagosomes 
within the cytosol (modified from Klionsky D.J. et al., 2016).  
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1.2 Lysosome: not only a degradative compartment   
Traditionally, lysosomes were considered merely to be waste bags involved in the 
degradation and recycling of cargoes mainly derived from the endocytic and the autophagic 
pathways (de Duve C., 2005). Recently, it has been reported that, besides their well-known 
digestive functions, lysosomal compartments are implicated in a plethora of other fundamental 
processes within the cell, including secretion, plasma membrane repair, signaling, energy 
metabolism, and immune response, and they are now considered crucial regulators of cell 
homeostasis (Settembre C. et al., 2013). Intriguingly, it has been also demonstrated that all 
lysosomal functions are globally regulated at transcriptional level by a lysosomal gene network, 
named CLEAR (Coordinated Lysosomal Expression and Regulation), and by its master gene 
TFEB (transcription factor EB). This lysosomal gene network includes co-regulated lysosomal 
genes that are involved in several lysosomal processes and functions, such as lysosomal 
biogenesis, lysosomal acidification, proteolytic activity of lysosomal enzymes, endocytosis, 
exocytosis, and autophagy. In particular, the master regulator of this network TFEB, belonging 
to the MiT/TFE (microphthalmia-transcription factor E) subfamily of bHLH-LZ (basic helix-
loop-helix leucine-zipper) transcription factors, promotes the transcription of approximately 
500 lysosomal genes by a direct binding to specific sites, called E-boxes, at their promoters 
(Sardiello M. et al., 2009; Palmieri M. et al., 2011).  
Among the lysosomal functions controlled by TFEB, one of the best characterized is 
lysosomal exocytosis, a two-step Ca2+-dependent process through which lysosomes secrete 
their luminal content into the extracellular matrix. It initially requires the docking of lysosomes 
to the close proximity of plasma membrane and then the increase in intracellular Ca2+ levels to 
promote lysosome fusion with the plasma membrane (Medina D.L. et al., 2011; Settembre C. 
et al., 2013). This process is involved in the elimination of cellular waste products, but it also 
promotes the release of degradative enzymes and other cargoes that may be essential to the 
clean-up and maintenance of the extracellular space (LaPlante J.M. et al., 2006). Moreover, it 
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mediates other important physiological functions, including plasma membrane repair, immune 
response, and bone resorption. Lysosomal exocytosis is very active in some cell types, such as 
haematopoietic cells, osteoclasts, and melanocytes. Interestingly, it has been reported that in 
this process TFEB is able to induce both docking and fusion of lysosomes with the plasma 
membrane, by raising intracellular Ca2+ levels through the activation of the lysosomal Ca2+ 
channel TRPML1 (Transient Receptor Potential Mucolipin 1) (Medina D.L. et al., 2011; 
Settembre C. et al., 2013). Moreover, upon release of lysosomal content, lipids and lysosomal 
membrane proteins, including LAMP1 and TRPML1, eventually fuse to plasma membrane and 
then are recycled back through endocytosis (Di Paola S. et al., 2018).  
Lysosomes play an important role also in nutrient sensing and in signalling pathways 
involved in cell metabolism and growth. These organelles sense the nutrient status of the cell 
through the LYNUS (lysosome nutrient sensing) complex, a machinery located to lysosomal 
surface and made of several interacting protein complexes, including the v-ATPase, Rag 
GTPases and the mammalian target of rapamycin complex 1 (mTORC1). Its main function is 
to regulate cell growth and metabolism through mTORC1 signalling pathway; in particular, 
LYNUS machinery responds to lysosomal amino acid content and signals to the nucleus to 
adapt to conditions of starvation or plenty (Settembre C. et al., 2013; Settembre C. and Ballabio 
A., 2014).  
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Fig.5 - Main functions of lysosomes. Lysosomes are involved in the degradation and recycling of 
extracellular material (via endocytosis) and intracellular components (via autophagy). In these 
processes, they fuse with late endosomes and autophagosomes, respectively. The resulting breakdown 
products are recycled to generate new cellular components and energy in response to the nutritional 
needs of the cell. Lysosomes also participates in Ca2+-regulated exocytosis to secrete their content into 
the extracellular space; this process is particular important in plasma membrane repair. More recently, 
lysosomes have been identified as signalling organelles that can sense nutrient availability and activate 
a lysosome-to‑nucleus signalling pathway that mediates the starvation response and regulates energy 
metabolism (modified from Settembre C. et al., 2013).  
 
1.3 Lysosome: a novel intracellular Ca2+-storing organelle 
In the last years lysosomes have also emerged as important Ca2+-storing compartments. 
Indeed, the average free calcium concentration within their lumen is approximately 200-600 
M (Christensen K.A. et al., 2002; Lloyd-Evans E. et al., 2008), and is thus comparable to the 
concentration within the main intracellular Ca2+ store, the endoplasmic reticulum (ER) 
(Bygrave F.L. and Benedetti A., 1996). Due to the high Ca2+ concentration within their acidic 
lumen, lysosomes - together with endosomes, lysosomes-related organelles (LRO), secretory 
granules, and the more distantly related acidocalcisomes and vacuoles - are often referred to as 
“acidic Ca2+ stores” (Patel S. and Docampo R., 2010).  
Despite being smaller in volume than ER, an increasing amount of experimental 
evidences have demonstrated that lysosomes play a central role in intracellular Ca2+ signaling 
and contribute to the regulation of intracellular Ca2+ homeostasis, in both physiological and 
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pathological conditions (Patel S. and Docampo R., 2010; Morgan A.J. et al., 2011). Under 
control conditions, Ca2+ can be mobilized from lysosomal stores to regulate a lot of Ca2+-
dependent functions, including signal transduction, organelle homeostasis and acidification, 
trafficking and fusion between lysosomes and other compartments, such as late endosomes, 
autophagosomes, and PM (Xu H. and Ren D., 2015). Furthermore, it has been reported that 
lysosomal Ca2+ signals necessary for the regulation of cellular functions can act locally, through 
microdomains of Ca2+ confined to small (10-100 nm) local areas, or propagate globally 
throughout the entire cell (Kilpatrick B.S. et al., 2016a). In this respect, it has been proposed 
that lysosomes can interact with other intracellular organelles, such as the ER, thus triggering 
a global Ca2+ signalling (Patel S. and Docampo R., 2010). 
To provide the ionic environment essential for proper lysosomal functions, lysosomal 
Ca2+ concentration is tightly controlled by the activation of several Ca2+-permeable channels 
and transporters located to lysosomal membrane. In particular, in the last years several Ca2+-
release channels have been shown to localize to endo-lysosomal membrane. These include 
some members of TRP (Transient Receptor Potential) channels (e.g. TRPMLs and TRPM2), 
TPCs (Two-Pore Channels) and P2X4 purinoceptor (Patel S. and Cai X., 2015). At present in 
metazoans little is known about how Ca2+ is taken up by the endo-lysosomal system (Brailoiu 
G.C. and Brailoiu E., 2016).     
 
 
 
 
 
 
 
Fig.6 - Main Ca2+-releasing channels localized to lysosomal membrane (modified from Zhong X.Z. 
and Dong X.P., 2015). 
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1.3.1 Ca2+ release mechanisms in the endo-lysosomal system 
Ca2+ release from acidic stores is promoted by a number of Ca2+-permeable channels 
located to the membranes of the endo-lysosomal system. Among them, a fundamental role is 
played by TRPML (Transient Receptor Potential Mucolipin subfamily) channels (Cheng X. et 
al., 2010; Grimm C. et al., 2012). However, other channels may contribute to the regulation of 
endo-lysosomal Ca2+ homeostasis, including TPCs (Two-Pore Channels) (Calcraft P.J. et al., 
2009; Morgan A.J. et al., 2011), TRPM2 (Transient Receptor Potential Melastatin 2) (Lange I. 
et al., 2009; Sumoza-Toledo A. and Penner R., 2011) and P2X4 (Qureshi O.S. et al., 2007; 
Huang P. et al., 2014). 
 
1.3.1.1 TRPMLs  
TRPML channels are members of Transient Receptor Potential (TRP) superfamily 
channels, a large family of cation channels expressed in almost every tissue and cell type. 
Members of this family exhibit varying degrees of selectivity for different ionic species and 
play an important role in the regulation of different cell functions, including sensory perception 
and signal transduction (Nilius B. et al., 2007; Earley S. and Brayden J.E., 2015). Similarly to 
all other TRPs, TRPMLs contain six transmembrane (6TM) domains, with both the N- and C-
termini residing in the cytoplasm and with the pore region occurring between TM5 and TM6 
domains (Cheng X. et al., 2010; Grimm C. et al., 2012). However, TRPMLs differ from the 
other TRP channels, since they have unusually short cytosolic tails, which range from 61 to 72 
amino acids (aa), and present a large luminal loop located between TM1 and TM2, which 
contains several N-glycosylation sites (Puertollano R. and Kiselyov K., 2009). TRPML proteins 
are also characterized by the presence of multiple positively charged aa residues at their N-
terminal end, which seems to be important for channels interaction with phosphoinositides 
(Dong X.P. et al., 2010). Furthermore, the presence of negatively charged glutamate and 
aspartate residues within the pore region defines TRPMLs selectivity to cations (Puertollano R. 
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and Kiselyov K., 2009). In mammals there are three TRPML proteins, TRPML1, TRPML2 and 
TRPML3 (also referred to as mucolipin 1-3 or MCOLN1-3), encoded by mcoln1-3 genes. They 
are relatively small proteins, consisting of <600 aa residues (Nilius B. et al., 2007), which share 
about 75% of similarity in the aa sequence, especially in the putative pore region between TM5 
and TM6 domains (Puertollano R. and Kiselyov K., 2009).  
 
 
 
 
 
 
Fig.7 - Topological structure of TRPML channels. TRPMLs are 6TM channels, with both N- and C-
termini located to the cytosol. They are predicted to form tetramers (4X). The cartoon on the left 
depicting human TRPML1 structure displays several mutations causing mucolipidosis type IV (MLIV). 
At present no human diseases have been associated with mutations in TRPML2 and TRPML3 proteins; 
however, mutations in TRPML3 are responsible for the varitint-waddler (Va) phenotype in mice 
(modified from Grimm C. et al., 2012). 
 
TRPML1 is a ubiquitously expressed protein with the highest expression level in brain, 
kidney, spleen, liver and heart (Cheng X. et al., 2010). In contrast to TRPML1, the tissue 
distribution pattern of TRPML2 and TRPML3 proteins is more restricted. Indeed, TRPML2 is 
predominantly expressed in kidney, liver, heart and in lymphoid organs, such as thymus and 
spleen (Cheng X. et al., 2010; Sun L. et al., 2015), whereas TRPML3 is mainly detected in 
cochlea, thymus, kidney, lung, eye, spleen, skin (melanocytes) and in somato-sensory neurons. 
At subcellular level, TRPML1 is expressed in late endosomes and lysosomes; TRPML2 
localized to the membranes of recycling endosomes, late endosomes and lysosomes; TRPML3 
is expressed in early endosomes, late endosomes and lysosomes, and also on plasma membrane 
(Cheng X. et al., 2010). The three mammalian TRPML channels are predicted to form tetramers 
(Grimm C. et al., 2012). In particular, they were shown to physically interact with each other, 
thus forming homo- and heteromultimers (Zeevi D.A. et al., 2007; Curcio-Morelli C. et al., 
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2010a; Venkatachalam K. et al., 2015); however, the protein-protein interactions between 
endogenous TRPMLs seem to be quite limited (Zeevi D.A. et al., 2009), probably due to the 
restricted tissue distribution pattern of TRPML2 and TRPML3. It is possible that variable 
assembly of TRPML proteins, which are differentially expressed in the target tissues, may result 
in tissue-specific channel characteristics (Curcio-Morelli C. et al., 2010a). Moreover, the 
biophysical properties and regulation of the heteromultimers may be different from the 
homomultimers, and this could contribute to the functional diversity of TRPMLs proteins 
(Venkatachalam K. et al., 2015). In addition, TRPMLs can also physically interact with TPCs, 
but it has been reported that the two family of channels function independently on endo-
lysosomal membranes (Yamaguchi S. et al., 2011). 
Functionally, TRPMLs constitute a family of inwardly rectifying (from endo-lysosomal 
lumen to cytosol) non-selective cation channels, mainly permeable to Ca2+, Na+ and K+, but not 
to H+ (Cheng X. et al., 2010). In addition, it has been reported that TRPML1 is also permeable 
to divalent heavy trace metals, such as Fe2+ and Zn2+ (Dong X.P. et al., 2008; Eichelsdoerfer 
J.L. et al., 2010; Grimm C. et al., 2012). However, despite their non-selectivity, it has been 
demonstrated that TRPML channels, and in particular TRPML1, the best characterized protein 
among this subfamily, play a major role in the regulation of endo-lysosomal Ca2+ homeostasis 
and endo-lysosomal functions, by promoting Ca2+ release from acidic organelles (LaPlante J.M. 
et al., 2002; Abe K. and Puertollano R., 2011). Lysosomal Ca2+ release via TRPMLs is 
promoted upon channel stimulation with PI(3,5)P2 (phosphatidylinositol 3,5-bisphosphate), a 
low-abundance endo-lysosomal-specific phosphoinositide, which binds specifically to the 
positively charged aa residues on the cytoplasmic N-terminus of TRPMLs (Dong X.P. et al., 
2010). Moreover, it was shown that TRPML1 is inhibited by the plasma membrane-specific 
phosphoinositide PI(4,5)P2 (phosphatidylinositol 4,5-bisphosphate), which, also binds to the 
positively charged aa on TRPML1 N-terminus (Zhang X. et al., 2012). It has been suggested 
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that PI(4,5)P2-mediated inhibition may be a mechanism to prevent the activation of lysosomal 
TRPML1 in non-native compartments, such as the plasma membrane (Xu H. and Ren D., 2015).  
Moreover, some researchers proposed that TRPML1 is also activated by NAADP 
(Nicotinic Acid Adenine Dinucleotide Phosphate) (Zhang F. and Li P.L., 2007; Zhang F. et al., 
2009; Zhang F. et al., 2011), the most potent Ca2+-releasing second messenger actually known, 
which is able to generate intracellular Ca2+ signals even at low nanomolar concentrations (Guse 
A.H. and Lee H.C., 2008). However, in literature some controversies about the activation of 
TRPML1 by NAADP emerged. Indeed, other researchers suggested that this channel did not 
participate in NAADP-mediated Ca2+ signaling (Pryor P.R. et al., 2006; Yamaguchi S. et al., 
2011), corroborating the evidence, already present in literature, that the molecular targets for 
NAADP action could be the endo-lysosomal TPCs (Brailoiu E. et al., 2009; Calcraft P.J. et al., 
2009; Zong X. et al., 2009).  
Mutations in mcoln1 gene are associated with mucolipidosis type IV (MLIV), a 
devastating lysosomal storage disorder characterized by neurodegeneration (Bargal R. et al., 
2000; Bassi T.M. et al., 2000; Sun M. et al., 2000). Moreover, mutations in murine mcoln3 
gene are responsible for the varitint-waddler (Va) phenotype, which is characterized by 
deafness and pigmentation defects in mice (Di Palma F. et al., 2002). Currently, no mutations 
in mcoln2 and mcoln3 genes have been associated with human diseases.  
 
1.3.1.2 TPCs 
TPCs (Two-Pore Channels) are a unique family of cation channels containing two 
repeats of a six transmembrane (2 x 6TM) pore-forming domain. For this structural feature, 
they represent an evolutionary intermediate between the tetrameric one-domain (6TM) 
channels – such as voltage-gated K+ channels (Kvs), TRPs, and sperm-specific Ca2+ channels 
(CatSpers) – and the monomeric four-domain (4 x 6TM) channels – such as voltage-gated Ca2+ 
channels (Cavs), and voltage-gated Na
+ channels (Navs) (Xu H. and Ren D., 2015). Each of the 
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two repeated 6TM domains contains a putative pore-forming region between TM5 and TM6 
(Morgan A.J. et al., 2011). Both N- and C-termini are hydrophilic and localizes to the cytoplasm 
(Ishibashi K. et al., 2000). In animal cells there are three TPC proteins, TPC1, TPC2 and TPC3, 
encoded by TPCN1-3 genes and consisting of approximately 800 aa residues (Grimm C. et al., 
2012). However, TPC3 protein is absent in many mammals such as mice, rats, and in most 
primates, including humans; indeed, it has been demonstrated that TPC3 gene degenerated into 
a pseudogene in the genomes of humans and other primates (Calcraft P.J. et al., 2009; Brailoiu 
E. et al., 2010). The primary sequences of the three proteins are quite different from one another 
(within a given species only ~20% identical, ~35% similar), but each orthologue is quite well 
conserved across species (40-90% identical, 55-93% similar) (Morgan A.J. et al., 2011). 
 
 
 
 
 
Fig.8 - Topological structure of TPC channels. This cartoon shows the structures of human TPC1 and 
TPC2 protein. They are composed of two repeats of a 6TM pore-forming domains, with both N- and C-
termini localized to the cytosol. They are predicted to form dimers (2X). Two polymorphisms in human 
TPC2 are associated with blond versus brown phenotype (modified from Grimm C. et al., 2012). 
 
TPC proteins are ubiquitously expressed, but differentially distributed in the endo-
lysosomal system: indeed, TPC1 and TPC3 are predominantly expressed in the endosomal 
compartments, whereas TPC2 mainly localizes to late endosomes and lysosomes (Calcraft P.J. 
et al., 2009; Morgan A.J. et al., 2011; Grimm C. et al., 2012). It has been reported that TPC 
proteins likely assembly in dimers to form one functional pore, thus maintaining the four-fold 
symmetry typical of voltage-gated ion channels (Patel S. and Cai X., 2015).  
TPC channels were traditionally studied for their role in the regulation of endo-
lysosomal Ca2+ homeostasis; indeed, several papers demonstrated that they promote Ca2+ efflux 
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from endo-lysosomes upon stimulation with the endogenous second messenger NAADP 
(Brailoiu E. et al., 2009; Calcraft P.J. et al., 2009; Zong X. et al., 2009). However, in the last 
years some controversies about the ionic permeability and selectivity of endo-lysosomal TPCs 
have emerged. Indeed, recent evidences suggested that these channels are highly selective for 
Na+ (TPC1: PNa/PK ~100; TPC2: PNa/PK ~30) (Wang X. et al., 2012; Cang et al., 2013; Kintzer 
A.F. and Stroud R.M., 2018). In particular, it has been proposed that TPC1 and TPC3 are 
voltage-gated cation channels, whereas TPC2 is a ligand-gated cation channel, activated by 
PI(3,5)P2 and potentially by NAADP (Kintzer A.F. and Stroud R.M., 2018). However, the ionic 
selectivity of TPC channels is still a matter of debate. 
To date, no disease-related mutations are known for human or rodent TPCs (Grimm C. 
et al., 2012). However, polymorphisms in human TPC2 have been associated to the control of 
hair pigmentation (Chao Y.K. et al., 2017). 
 
1.3.1.3 TRPM2 
TRPM2 (Transient Receptor Potential Melastatin 2) is a non-selective, Ca2+-permeable 
cation channel belonging to the melastatin subfamily of TRP channels. Like other TRPs, its 
structure comprises 6TM domains, with intracellular N- and C-termini and a pore-forming loop 
between TM5 and TM6 domains (Sumoza-Toledo A. and Penner R., 2011). Interestingly, the 
channel contains a unique adenosine diphosphate ribose (ADPR) hydrolase domain (Nudix-like 
domain) in its C-terminus, by virtue of which it is considered a “chanzyme” – a channel with 
enzymatic activity (Perraud A.L. et al., 2001; Patel S. and Docampo R., 2009). In humans, the 
~6.5 kb TRPM2 transcript encodes a protein of ~1500 aa. This protein is expressed at high 
levels in the brain, but it has been also detected in other tissues, including bone marrow, spleen, 
heart, liver and lung, and in different cell types such as pancreatic -cells, endothelial cells, 
microglia, neurons, cardiomyocytes and immune cells (Sumoza-Toledo A. and Penner R., 
2011). Although it is primarily expressed at the plasma membrane, where it mediates Ca2+ 
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influx into the cell, it also localizes to lysosomal membrane, where it acts as a Ca2+-release 
channel (Lange I. et al., 2009; Sumoza-Toledo A. and Penner R., 2011). Its endogenous 
activator is the cytosolic second messenger ADPR (ADP-ribose) (Perraud A.L. et al., 2001), 
which binds to the Nudix-like domain in TRPM2 C-terminus and is subsequently hydrolyzed 
to ribose 5-phosphate and AMP. Since AMP antagonizes ADPR-mediated gating of TRPM2, 
it has been proposed that the enzymatic activity of the channel may provide a negative feedback 
inhibition for TRPM2 activity (Sumoza-Toledo A. and Penner R., 2011).  Currently, a specific 
association of lysosomal TRPM2 channel with human diseases has not been found (Sterea A.M. 
et al., 2018). 
 
1.3.1.4 P2X4 
The ionotropic P2X receptors are a family of Ca2+-permeable non-selective cation 
channels localized to plasma membrane and activated by extracellular ATP (adenosine 5’-
triphosphate). Among the members of this family, only P2X4 is localized intracellularly to the 
membranes of late endosomes and lysosomes (Qureshi O.S. et al., 2007; Huang P. et al., 2014). 
Like other P2X receptors, it contains two transmembrane regions and form trimers (Patel S. and 
Cai X., 2015; Suurvali J. et al., 2017). P2X4 receptor was found to be localized to lysosomal 
membrane of some mammalian cells, including rat microglia, macrophages and endothelial 
cells, where it promotes Ca2+ efflux from lysosomes (Qureshi O.S. et al., 2007). Lysosomal 
P2X4 is activated by luminal ATP (Qureshi O.S. et al., 2007; Huang P. et al., 2014), with an 
ATP-binding site located within the lysosomal lumen (Morgan A.J. et al., 2011; Patel S. and 
Cai X., 2015). It has been reported that this channel is regulated by luminal pH: indeed, while 
the acidic pH (~4.5) at the luminal side inhibits P2X4 activity, an increase in luminal pH in the 
presence of intra-luminal ATP causes the activation of the channel. This evidence suggests that 
lysosomal P2X4 is normally inactivated or minimally activated at the resting lysosomal pH 
(4.5-5.0) (Huang P. et al., 2014).  
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1.3.2 Ca2+ uptake mechanisms in the endo-lysosomal system 
To date, a complete knowledge regarding the molecular mechanisms for endo-
lysosomal Ca2+ uptake in metazoans is still lacking. In these organisms, Ca2+ influx within the 
endo-lysosomal compartments occurs via a mechanism poorly characterized, which seems to 
be dependent on the H+ gradient generated by the v-ATPase. Indeed, v-ATPase inhibition, by 
causing an increase in lysosomal pH, leads to lysosomal Ca2+ release; by contrast, lysosomal 
reacidification is accompanied by a lysosomal Ca2+ refilling (Christensen K.A. et al., 2002). On 
the basis of these evidences, it has been proposed that a Ca2+/H+ exchanger (CAX) could be 
responsible, at least in part, for pH-dependent Ca2+ uptake into lysosomes (Morgan A.J. et al.., 
2011). This exchanger is known to be involved in the better-characterized mechanism of Ca2+ 
uptake by plant and yeast vacuoles, acidic organelles that are equivalent of lysosomes in animal 
cells. It uses the proton gradient across the vacuolar membrane to drive Ca2+ influx into the 
lumen (Pittman J.K., 2011). However, CAX genes are not widespread in all metazoan kingdom, 
and, although the genes related to yeast/plant CAX have been recently described in some 
vertebrates, including some echinoderm, mollusk, fish, amphibian and non-placental mammals, 
they are absent in the genome of placental mammals (Melchionda et al., 2016). This evidence 
suggests that in placental mammals CAX proteins are not involved in lysosomal Ca2+ uptake 
and that in these animals different mechanisms control lysosomal Ca2+ uptake, compared with 
lower order organisms and non placental mammals (Lloyd-Evans E., 2016a). Moreover, in plant 
and yeast vacuoles lysosomal Ca2+ uptake is also mediated by the action of a Ca2+-ATPase, 
which transports Ca2+ against its concentration gradient from the cytosol into the vacuolar 
lumen (Patel S. and Docampo R., 2010; Pittman J.K., 2011). However, it is unknown whether 
this pump is also expressed in the endo-lysosomal system of animal cells (Patel S. and Docampo 
R., 2010). Probably in placental mammals lysosomal Ca2+ uptake may not be mediated by a 
single transporter, but rather it requires the concerted action of putative Na+/H+ and Na+/Ca2+ 
exchangers, acting in series. The net effect of this coupled transport is Ca2+ influx into 
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lysosomal lumen and H+ efflux from lysosomal lumen (Patel S. and Docampo R., 2010; Morgan 
A.J. et al., 2011; Brailoiu G.C. and Brailoiu E., 2016).  
However, very recently Garrity et al. have suggested that Ca2+ uptake into lysosomes is 
not dependent on lysosomal acidification, but the ER seems to be responsible for lysosomal 
Ca2+ refilling. In particular, the authors have shown that the depletion of ER Ca2+ stores 
obtained by using SERCA inhibitors abolished lysosomal Ca2+ refilling. Furthermore, the 
inhibition of IP3Rs, but not of RyRs, on ER membrane blocked lysosomal Ca
2+ replenishment 
by ER (Garrity A.G. et al., 2016). 
 
1.4  TRPML1: the main Ca2+ release channel in the lysosome 
Among the members of TRPMLs, the most important and the best characterized protein 
is TRPML1. TRPML1 acts as an inwardly rectifying, non-selective channel permeable to Ca2+ 
and other cations, including Na+ and K+ (LaPlante J.M. et al., 2002; Cheng X. et al., 2010; Abe 
K. and Puertollano R., 2011). Moreover, the channel is also able to mobilize heavy metals, such 
as Fe2+ and Zn2+, from lysosomal lumen to cytosol (Dong X.P. et al., 2008; Eichelsdoerfer J.L. 
et al., 2010; Grimm C. et al., 2012).  Despite being a non-selective cation channel, it is thought 
that the main physiological function of TRPML1 is to promote Ca2+ release from late 
endosomes and lysosomes (LaPlante J.M. et al., 2002; Abe K. and Puertollano R., 2011).   
Human TRPML1 protein is encoded by mcoln1 gene localized on chromosome 19 
(19p13.2-13.3) (Slaugenhaupt S.A. et al., 1999; Bargal R. et al., 2000; Bassi T.M. et al., 2000; 
Sun M. et al., 2000). TRPML1 is a 580 aa long six-pass transmembrane channel with a 
molecular weight of ~65 kDa. Similarly to other TRPs, both its N- and C-terminal tails are 
exposed to the cytosol. Interestingly, the two cytosolic tails contain two independent di-leucine 
motifs, which regulate TRPML1 delivery to late endosomes and lysosomes. In particular, the 
N-terminal di-leucine motif (L15L) promotes the direct transport of TRPML1 from the TGN to 
early endosomes and subsequently to lysosomes, through a mechanism that involves the adaptor 
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protein-1 (AP-1). The C-terminal di-leucine motif (L577L), instead, is involved in the indirect 
transport of TRPML1 from the TGN to plasma membrane, followed by its internalization and 
sequential delivery to early endosomes, late endosomes and finally lysosomes; the trafficking 
of TRPML1 through this indirect route plays a marginal role in TRPML1 delivery to late 
endosomes and lysosomes and requires the adaptor protein-2 (AP-2). Moreover, some post-
translational modifications have been reported to play an important role in the regulation of 
TRPML1 trafficking and function. For example, the C-terminus of TRPML1 contains three 
cysteine residues (C565CC) that can be palmitoylated in order to ensure the association of 
TRPML1 with the late endosomal/lysosomal membranes (Vergarajauregui S. and Puertollano 
R., 2006). In addition, phosphorylation is an important modification that regulates protein 
activity. Indeed, protein kinase A (PKA) is able to phosphorylate TRPML1 in its C-terminal 
tail on S557 and S559, thus negatively regulating channel activity. Since these phosphorylation 
sites are distant from the pore region located between TM5 and TM6 domains, it is possible 
that phosphorylation affects the interaction between TRPML1 subunits or with other TRP 
channels (Vergarajauregui S. et al., 2008a). TRPML1 C-terminus can be phosphorylated also 
by protein kinase D (PKD); this modification seems to be important for the trafficking of 
TRPML1 from the Golgi apparatus to the lysosomes (Marks D.L. et al., 2012).  
Furthermore, the large loop between the first (TM1) and the second (TM2) 
transmembrane domains contains four N-glycosylation sites. It has been reported that this loop 
can be cleaved between the second and third glycosylation sites (R200↓P201) by the lysosomal 
enzyme cathepsin B. The proteolytic cleavage of TRPML1, which occurs late in the 
biosynthetic pathway at a post-Golgi compartment, is a regulatory mechanism to inhibit 
TRPML1 channel activity (Kiselyov K. et al., 2005; Miedel M.T. et al., 2006).  
Like other members of mucolipin subfamily of TRPs, TRPML1 activity is modulated 
by phosphoinositides (PIPs): indeed, the channel is strongly activated by the endo-lysosomal-
specific phosphoinositide PI(3,5)P2 (Dong X.P. et al., 2010), while it is inhibited by the plasma 
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membrane-localized phosphoinositide PI(4,5)P2 (Zhang X. et al., 2012). Both the molecules 
are reported to bind to a stretch of positively charged aa located at the N-terminus of TRPML1; 
in particular, it seems that aa R42/R43/R44 participate in the binding of PI(3,5)P2, while aa R
61/K62 
are involved in the binding of PI(4,5)P2 (Zhang X. et al., 2012). However, also the endogenous 
second messenger NAADP has been shown to activate the channel (Zhang F. and Li P.L., 2007; 
Zhang F. et al., 2009; Zhang F. et al., 2011).  
 
1.4.1 Mutations in mcoln1 gene and mucolipidosis type IV (MLIV) 
Loss-of-function mutations in human mcoln1 gene are responsible for mucolipidosis 
type IV (MLIV) (OMIM #252650) (Bargal R. et al., 2000; Bassi T.M. et al., 2000; Sun M. et 
al., 2000), an autosomal recessive lysosomal storage disorder (LSD) first described by Berman 
and colleagues in 1974 (Berman E.R. et al., 1974). Clinically, the disease is characterized by 
neurodegeneration, progressive and severe psychomotor retardation, ophthalmological defects, 
iron deficiency and constitutive achlorhydria (Amir N. et al., 1987; Bach G., 2001; Altarescu 
G. et al., 2002). Typically, the first symptoms appear early during the childhood (~1-2 years of 
age), but, after the onset, the clinical progression of the disease is very slow for the first 2-3 
decades of life. Individuals with MLIV typically survive to early adulthood and, although their 
life expectancy is not so clear, patients in their thirties and forties have often been reported 
(Bach G. et al., 2005).  Electron microscopy studies revealed that MLIV cells from every tissue 
and organ are characterized by the accumulation of enlarged endosomal/lysosomal 
compartments in which undigested lipid products accumulate; in particular, the storage 
materials in this disease are more heterogeneous than in the other LSDs, and include 
sphingolipids (specifically gangliosides), acid mucopolysaccharides, phospholipids, and 
lipofuscin (Bach G. et al., 1975; Bach G. et al., 1977; Bargal R. and Bach G., 1988; Morgan 
A.J. et al., 2011). The abnormal accumulation of lipids within MLIV cells is the result of their 
retention within the acidic organelles, delayed metabolism, and reduced trafficking to the 
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plasma membrane and Golgi apparatus. Thus, the storage occurring in MLIV is associated with 
an impairment in lysosomal sorting and/or trafficking of lipids along the late steps of the 
endocytic pathway, and with defects in lipid metabolism (Bargal R. and Bach G., 1997; Chen 
C.S. et al., 1998; Jansen S.M. et al., 2001; Venkatachalam K. et al., 2015). However, unlike 
most other storage diseases, the activity of lysosomal hydrolytic enzymes participating in the 
catabolism of the stored molecules seems to be unaltered (Chen C.S. et al., 1998).  
Concerning the epidemiology of mucolipidosis type IV, the disease is a pan-ethnic 
disorder that appears rarely in the general population, but it has been observed with a relatively 
high frequency among Ashkenazi Jewish population; indeed, approximately 70-80% of patients 
diagnosed with MLIV have Ashkenazi Jewish origin (Raas-Rothschild A. et al., 1999; Bach 
G., 2001).  
In 1999 the gene causing MLIV was mapped to human chromosome 19p13.2-13.3, in a 
region of approximately 1 cM, by linkage analysis using 13 Ashkenazi Jewish families 
(Slaugenhaupt S.A. et al., 1999). Later, in 2000, mcoln1 gene was independently cloned by 
three research groups, which identified different mutations in mcoln1 gene, including two major 
founder mutations causing MLIV in Ashkenazi Jewish population and accounting for ~95% of 
the mutations in MLIV patients: (1) an A→G transition in the 3’ acceptor splice site of intron 
3, resulting in an aberrant splicing and in the skipping of exon 4 and 5 (associated with the 
major Ashkenazi haplotype; ~72% of the alleles); (2) a deletion of ~6000 bp spanning exons 1-
6 and the first part of exon 7 (associated with the minor Ashkenazi haplotype; ~23% of the 
alleles) (Bargal R. et al., 2000; Bassi T.M. et al., 2000; Sun M. et al., 2000). Today, more than 
20 different MLIV-causing mutations, including nonsense and missense mutations and an in-
frame deletion, have been identified throughout the mcoln1 gene, in both loops and 
transmembrane regions of the channel. These mutations can lead to non-functional protein, 
mislocalized protein, or short versions of the protein (Wakabayashi K. et al., 2011; Grimm C. 
and Cuajungco M.P., 2014, Venkatachalam K. et al., 2015). Indeed, many patients carry 
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mutations that introduce premature stop codons in the gene; as a result, the protein is absent or 
abnormally short, and thus not functional. However, some patients carry single point mutations 
(i.e. F408 and F465L) that make the channel partially inactive on stimulation with endogenous 
ligands (Chen C.C. et al., 2014). 
 
 
 
 
 
 
 
Fig.9 - MLIV-causing mutations in TRPML1 protein. MLIV-causing mutations are reported to occur 
in the aa residues located in both loops and transmembrane regions. Missense mutations causing amino 
acid substitution are indicated in blue; mutations causing premature stop codon (X) or in-frame deletion 
() are indicated in red (modified from Venkatachalam K. et al., 2015).  
 
 
 
  
 
 
 
 
 
Table 1 - Mutations identified in patients with MLIV. Several mutations have been identified in 
MLIV patients. Most of them are missense mutations, but also frameshift mutations, splice-site 
mutations, deletions, and insertions have been reported to cause the disease (modified from Wakabayashi 
K. et al., 2011). 
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Cloning of mcoln1 gene led to the identification of two additional members of the 
mucolipin gene family, mcoln2 and mcoln3. Mutations in mcoln3 gene are reported to cause 
deafness, circling behaviour, sterility, and pigmentation defects in mice (Di Palma F. et al., 
2002). To date, no human diseases have been linked to mutations in mcoln2 and mcoln3 genes.  
 
1.4.2 Determination of TRPML1 molecular structure 
In the last years, many efforts have been made by researchers in an attempt to determine 
the molecular structure of TRPML1 protein. Their studies led to the publication of multiple 
conformations of TRPML1, mainly using electron cryo-microscopy. In the beginning of 2017, 
Li M. et al. have resolved the first high-resolution crystal structure of the long linker between 
the first two transmembrane segments (TM1 and TM2) of human TRPML1 (Li M. et al., 2017). 
This region, which constitutes a large part of the channel (more than one-third of the channel’s 
length), is the site of three missense mutations causing MLIV (Wakabayashi K. et al., 2011; 
Venkatachalam K. et al., 2015). The researchers showed that this linker is able to form a tight 
tetramer with a highly electronegative central pore which is particularly important in the 
regulation of TRPML1 by luminal Ca2+ and pH. In addition, they demonstrated that the three 
MLIV-causing mutations in the luminal linker were able to disrupt the structure of the luminal 
pore and the tetrameric assembly of the full-length channel, thus determining its mislocalization 
within the cell (Li M. et al., 2017). Moreover, in the same year Schmiege et al. have determined 
the electron cryo-microscopy structure of full-length human TRPML1. They demonstrated that 
TRPML1 has a topology similar to other TRP channels and forms the canonical homotetrameric 
assembly in which the ion channel is formed at its centre. Interestingly, the researchers also 
resolved the structure of the channel in an open conformation, bound to its agonist ML-SA1. 
They showed that this synthetic compound binds within a hydrophobic pocket created by two 
TRPML1 subunits, inducing conformational changes that allow Ca2+ efflux across the channel 
(Schmiege P. et al., 2017). Recently, Chen et al. resolved the electron cryo-microscopy 
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structure of mouse TRPML1 channel (91% primary sequence similarity to human TRPML1) 
embedded in nanodiscs, characterizing the PI(3,5)P2-binding site at the N-terminus of the 
channel, distal from the pore region (Chen Q. et al., 2017). Finally, Zhang et al. presented the 
structure of mouse TRPML1 in lipid nanodiscs and Amphipols, and, based on their structural 
analysis, they proposed that the channel is regulated by pH, Ca2+ and phosphoinositides in a 
combined and different manner, depending on its subcellular localization (plasma membrane – 
late endosomes – lysosomes) along the endocytosis/exocytosis pathways (Zhang S. et al., 
2017).  
 
1.4.3 TRPML1 interacting proteins 
In recent years, some proteins that physically interact with TRPML1 have been 
identified. An important TRPML1 interactor is ALG-2 (Alix-Apoptosis-Linked Gene-2), a Ca2+-
binding protein belonging to the penta-EF hand protein family. This protein, that could act as a 
lysosomal Ca2+ sensor, is able to bind in a Ca2+-dependent manner to a stretch of charged and 
hydrophobic aa located to the N-terminus of TRPML1. It has been proposed that the binding of 
ALG-2 to TRPML1 plays an important role in the regulation of the distribution and function of 
TRPML1 along the late endosomal-lysosomal pathway (Vergarajauregui S. et al., 2009). 
TRPML1 was also found to interact with the three members of the Lysosomal-Associated 
Protein Transmembrane (LAPTM) family (LAPTM4a, LAPTM4b, and LAPTM5), which 
participate in the transport of small molecules across intracellular membranes. This association, 
occurring at the level of the late endosomes and lysosomes, suggested a novel role for LAPTM 
proteins in the regulation of lysosomal function (Vergarajauregui S. et al., 2011). TRPML1 also 
associates with Hsc70 and Hsp40, two members of a molecular chaperone complex involved in 
protein transport into the lysosome during Chaperone-Mediated Autophagy (CMA). It has been 
hypothesized that the interaction of TRPML1 with these proteins may be required for proper 
CMA function (Venugopal B. et al., 2009). Furthermore, Spooner et al. recently performed a 
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systematic screen for TRPML1 interactors, identifying some potential proteins that could 
interact with the channel (i.e. STOML1, Rac2, Cdc42, P5KTI, and NP9). However, further 
studies are needed to validate the interaction of these candidate interactor proteins with the 
lysosomal channel (Spooner E. et al., 2013). Finally, TRPML1 has also been reported to interact 
with TPC channels, although it seems that the two families of channels function independently 
in lysosomes (Yamaguchi S. et al., 2011).    
 
1.4.4  Lysosomal functions mediated by TRPML1 
A growing body of experimental evidences has demonstrated that Ca2+ released through 
TRPML1 channel play a fundamental role in a plethora of lysosomal processes, including 
lysosomal exocytosis (Medina D.L. et al., 2011; Settembre C. et al., 2013), phagocytosis 
(Samie M. et al., 2013), lysosomal biogenesis, size and trafficking (Treusch S. et al., 2004; 
Shen D. et al., 2012; Cao Q. et al., 2017), regulation of autophagy (Medina D.L. et al., 2015; 
Zhang X. et al., 2016),  and lysosomal motility and positioning (Li X. et al., 2016).  
   
1.4.4.1 Lysosomal exocytosis 
Different research groups demonstrated that TRPML1 is involved in lysosomal 
exocytosis. The first evidence suggesting an active role for TRPML1 in this process date back 
to 2006, when LaPlante et al. revealed that lysosomal exocytosis was dramatically impaired in 
fibroblasts from MLIV patients, carrying loss-of-function mutations in TRPML1. Interestingly, 
they found that the dysfunction observed could be efficiently corrected by transfecting the 
MILV cells with the wild-type TRPML1 cDNA (LaPlante J.M. et al., 2006). The involvement 
of the channel in lysosomal exocytosis was confirmed by another paper, in which the authors 
showed that lysosomal exocytosis was increased in cells expressing gain-of-function mutations 
in TRPML1, via a mechanism that is dependent on lysosomal Ca2+ release (Dong X.P. et al., 
2009). These evidences suggest that TRPML1 may promote lysosomal Ca2+ release to induce 
37 
 
lysosomal exocytosis. In this regard, the involvement of TRPML1 in this process was further 
corroborated by the discovery that TFEB, a master regulator of several lysosomal functions, 
controls not only the gene encoding for TRPML1, but also the process of lysosomal exocytosis. 
Indeed, in 2011 Medina et al. reported that in TFEB-overexpressing cells the silencing of 
TRPML1 abolished the increase in intracellular Ca2+ concentration mediated by TFEB, thus 
inhibiting lysosomal exocytosis. Accordingly, in human MLIV cells that carried loss-of-
function mutation of the channel, Ca2+ levels were not affected by TFEB overexpression and 
lysosomal exocytosis was not induced. Moreover, the depletion of TRPML1 impaired TFEB-
mediated fusion of lysosomes with the plasma membrane, and inhibited the secretion of 
lysosomal enzymes into the extracellular medium. These results suggest that TFEB modulates 
lysosomal exocytosis by triggering intracellular Ca2+ elevation through TRPML1 (Medina D.L. 
et al., 2011).    
 
1.4.4.2 Phagocytosis 
TRPML1 is also involved in the phagocytosis and clearance of large extracellular 
particles in macrophage cells. Phagocytosis of large particles, such as apoptotic bodies, is 
known to require the delivery of endosomal and lysosomal membranes to form plasmalemmal 
pseudopods (Czibener C. et al., 2006). In a recent paper, Samie et al. showed that the binding 
of large particles to macrophages triggered an increase in PI(3,5)P2 levels, which promoted 
transient Ca2+ release through TRPML1, locally at the sites of uptake. This phenomenon 
contributed to phagosome biogenesis by rapidly delivering lysosomal membrane to nascent 
phagosomes via focal exocytosis, thus leading to the clearance of senescent and apoptotic cells. 
The involvement of TRPML1 in phagocytosis has been demonstrated by the evidence that both 
particle ingestion and lysosomal exocytosis were blocked by the pharmacological inhibition of 
TRPML1 and were defective in macrophages isolated from TRPML1 knock out mice. By 
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contrast, TRPML1 overexpression or its pharmacological activation facilitated both the 
processes (Samie M. et al., 2013). 
 
1.4.4.3 Lysosomal biogenesis, size and trafficking  
Cells lacking TRPML1 are characterized by profound defects in the late 
endosomal/lysosomal compartments. Mutations in cup-5, the C.elegans functional ortholog of 
the mammalian TRPML1, cause a block/delay in the complete maturation of lysosomes and 
lead to the accumulation of aberrant large vacuoles that are hybrids of late endosomes and 
lysosomes (LELs). These alterations indicate a defect in lysosomal biogenesis and reformation 
from hybrid organelles (Treusch S. et al., 2004). A similar accumulation of enlarged LELs has 
also been observed in cells from Drosophila trpml mutants (Venkatachalam K. et al., 2008) and 
in cells from TRPML1 knock out mice (Venugopal B. et al., 2007).  
It has been proposed that TRPML1 exerts a crucial function also in the control of 
lysosome size. Indeed, in yeast a pivotal role in the regulation of vacuole size is played by 
PI(3,5)P2, the endogenous activator of the channel. PI(3,5)P2 deficiency was accompanied by a 
dramatic increase in vacuole size and defects in multivesicular bodies (MVB) sorting; in 
contrast, high levels of PI(3,5)P2 caused organelle shrinkage and fragmentation (Efe J.A. et al., 
2005). Also in mammals PI(3,5)P2 deficiency led to the enlargement of vacuoles/LELs and to 
trafficking defects (Dong X.P. et al., 2010). Moreover, TRPML1-/- cells from MLIV patients 
displayed an accumulation of enlarged endosomal/lysosomal compartments, in which lipids 
and other biomaterials accumulated, suggesting profound defects in lysosomal biogenesis and 
trafficking (Chen X. et al., 2010). In 2017 Cao et al. have demonstrated the direct involvement 
of TRPML1 in the regulation of lysosomal size in mammalian cells. Indeed, TRPML1 
upregulation, by activating calmodulin, was able to suppress in a Ca2+-dependent manner the 
formation of enlarged lysosomes/vacuoles induced by the chemical vacuolin-1 or by the 
activation of P2X4 receptor. These data supported the predominant role of TRPML1 in 
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lysosome fission. Considering the involvement of lysosome fission in the processes of lysosome 
biogenesis and reformation, it has been suggested that TRPML1 could mediate the reformation 
of lysosomes from hybrid organelles formed after fusion with late endosomes or 
autophagosomes, thus participating in lysosome biogenesis (Cao Q. et al., 2017). 
Furthermore, the lack of TRPML1 has also been associated with multiple trafficking 
defects, including the retrograde transport of some lipid molecules to the TGN and the transport 
and degradation of different substrates into the lysosomes (Di Paola S. et al., 2018). In 
particular, the LEL-to-TGN retrograde trafficking is impaired in MLIV cells, since 
lactosylceramide, a lipid normally localized to the Golgi apparatus, accumulated in lysosomes, 
thus suggesting that lipid trafficking (the exit of lipids from late endosomes and lysosomes) is 
impaired in the absence of TRPML1 (Chen C.S. et al., 1998). Moreover, defects in components 
of the intracellular cholesterol/lipid trafficking pathway are commonly associated with another 
severe lysosomal storage disorder, the Niemann-Pick type C (NPC) disease (Rosenbaum A.I. 
and Maxfield F.R., 2011). In 2012 Shen et al. reported that the increase in TRPML1 expression 
and activity was sufficient to correct the lysosomal trafficking defects and reduced cholesterol 
accumulation in NPC cells (Shen D. et al., 2012).  
Collectively, all these evidences suggest that the activation of TRPML1 is required for 
the regulation of lysosomal biogenesis, size and intracellular trafficking.  
 
1.4.4.4 Regulation of autophagy 
Several experimental evidences demonstrated the crucial role of TRPML1 in the 
regulation of the autophagic process. In human fibroblasts derived from MLIV patients, the 
impairment of the autophagic pathway induced a significant accumulation of the autophagic 
markers p62 and LC3-II, as a result of increased autophagosome formation and delayed 
autophagosome fusion with lysosomes. These alterations led to an inefficient autophagosome 
degradation (Vergarajauregui S. et al., 2008b). A similar increase in p62 and LC3-II was also 
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observed in neuronal cells derived from mcoln1-/- mouse, a murine model of MLIV. This finding 
suggested an accumulation of protein aggregates and a defect in autophagy which could account 
for the neurodegeneration occurring in MLIV (Curcio-Morelli C. et al., 2010b). Autophagic 
defects have also been described in other animal models of MLIV, including Drosophila trpml 
mutant and C.elegans cup-5 null mutant. In particular, the disruption in autophagy observed in 
trpml mutant flies, which exhibited a MLIV-like phenotype, was attributable to a reduced 
degradation of cargoes following fusion between autophagosomes and lysosomes 
(Venkatachalam K. et al., 2008). Similarly, in C.elegans mutations in cup-5 are responsible for 
defects in the autophagic pathway. Indeed, in cup-5 null mutant worms, a variety of autophagic 
substrates accumulated in enlarged vacuoles similar to late endosomes and lysosomes, thus 
indicating a dysfunction in the proteolytic degradation of autolysosomes (Sun T. et al., 2011). 
However, a deepen knowledge about the molecular mechanisms underlying TRPML1-
mediated regulation of autophagy came from recent studies performed in mammalian cells. In 
example, in 2015 Medina et al. demonstrated that lysosomal Ca2+ release through TRPML1, by 
activating the Ca2+-dependent Ser/Thr phosphatase calcineurin (CaN), promoted TFEB nuclear 
translocation and TFEB-mediated transcription of the autophagic genes. Interestingly, the 
inhibition of TRPML1, by preventing the cytoplasm-to-nucleus shuttling of TFEB, hampered 
the transcription of the autophagic genes, thus determining a block in the autophagic process 
(Medina D.L. et al., 2015). Furthermore, it has been proven that autophagy can also be activated 
by lysosomal Ca2+ release through TRPML1 in response to oxidative stress conditions. Indeed, 
following an elevation in ROS production (for example, due to mitochondrial damage) or an 
increase in exogenous oxidants, TRPML1-mediated Ca2+ release promoted CaN-dependent 
TFEB nuclear translocation, thus enhancing both autophagy and lysosome biogenesis. In this 
way, TRPML1 acted as a ROS sensor activated upon elevations in ROS levels, which could 
reduce oxidative stress in the cell. Indeed, the subsequent increase in the autophagic flux 
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mediated by the lysosomal channel could facilitate the elimination of damaged mitochondria 
and excessive ROS, thus restoring the cellular redox homeostasis (Zhang X. et al., 2016).  
 
1.4.4.5 Lysosomal motility and positioning   
In 2016 Li et al. have demonstrated that upon nutrient starvation TRPML1 activity is 
also required to promote Ca2+-dependent centripetal movement of lysosomes towards the 
perinuclear region of the cell. The authors showed that under resting conditions lysosomes were 
scattered throughout the cytoplasm, while during autophagy these organelles were recruited to 
the perinuclear area, where autophagosomes accumulated, in a mechanism mediated by 
TRPML1. Indeed, TRPML1-mediated Ca2+ release activated the Ca2+-binding protein ALG-2, 
which bound to TRPML1 and, in turn, recruited the dynein-dynactin complex required for 
centripetal movement of lysosomes. Following their accumulation in close proximity to the 
nucleus, lysosomes fused with autophagosomes, thus promoting the formation of 
autolysosomes (Li X. et al., 2016).   
 
 
1.5 Physical and functional coupling between lysosomes and ER 
Accumulating evidences demonstrated the existence of a physical and functional 
crosstalk between lysosomes and ER in different types of animal cells. Lysosomes/ER 
interaction seems to occur at membrane contact sites (MCSs), restricted regions between two 
membranes that are in close proximity (typically less than 30 nm separation). These restricted 
spaces, functionally referred to as microdomains or nanojunctions, act as platforms for the 
exchange of small molecules and ions, including Ca2+, between different compartments 
(Burgoyne T. et al., 2015; Penny C.J. et al., 2015; Aston D. et al., 2017). Interestingly, it has 
been estimated that 80-100% of lysosomes forms MCSs with the ER, thus suggesting a 
42 
 
functional role for the physical coupling between these two Ca2+ stores in the regulation of 
intracellular Ca2+ homeostasis (Burgoyne T. et al., 2015; La Rovere R.M.L. et al., 2016).  
Concerning the mechanisms underlying Ca2+ exchange between lysosomes and ER, it 
has been proposed that the two compartments could interact at least in two ways: in a first 
model, Ca2+ released from acidic stores can be sequestered by the ER, priming the latter for 
enhanced release (Lee H.C. et al., 2012). This mechanism has been proposed to account for the 
NAADP-induced Ca2+ oscillation observed in sea urchin eggs (Churchill G.C. and Galione A., 
2001) and the excitation-contraction coupling in guinea-pig atrial myocytes (Collins T.P. et al., 
2011). Alternatively, according to the so-called “trigger” hypothesis, the Ca2+-mobilizing 
second messenger NAADP initiates a small local Ca2+ release from acidic Ca2+ stores that is 
subsequently amplified by ER Ca2+ release. In particular, it has been proposed that Ca2+ released 
through lysosomal channels (i.e. TPCs) upon stimulation with NAADP (local signalling) could 
sensitizes the neighbouring ER Ca2+ channels (IP3Rs and/or RyRs) to mediate further Ca
2+ 
release from ER via Ca2+-induced Ca2+ release (CICR) mechanism (global signalling) (Cancela 
J.M. et al., 1999; Patel S. and Docampo R., 2010; Lee H.C. et al., 2012). The crosstalk (“channel 
chatter”) between lysosomal and ER Ca2+ channels is responsible for the so-called 
“anterograde” Ca2+ signaling (from lysosomes to ER). This mechanism was proposed to 
account for the blockage of the cholecystokinin (CKK)-activated and NAADP-dependent Ca2+ 
release in mouse pancreatic acinar cells by antagonists of the RyRs and IP3Rs (Cancela J.M. et 
al., 1999; Lee H.C. et al., 2012).  
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Fig.10 - NAADP-mediated “channel chatter” between lysosomal and ER Ca2+ channels. Schematic 
showing the proposed mechanism of action of NAADP, according to the “trigger” hypothesis. The 
activation of lysosomal Ca2+ channels by NAADP generates a local Ca2+ signalling from acidic Ca2+ 
stores, which is subsequently amplified by ER Ca2+ channels, thus resulting in a global Ca2+ signalling 
(modified from Patel S. and Docampo R., 2010). 
 
However, it has been recently demonstrated that the dialogue between the two 
compartments can be bidirectional. Indeed, in addition to the above-mentioned “anterograde” 
Ca2+ signalling, the communication can also occur in the reverse “retrograde” direction (from 
ER to lysosomes). The first evidence of a retrograde Ca2+ signalling was provided in 2013 by 
Morgan et al., who discovered this reverse communication in sea urchin eggs. In these cells, 
ER could signal back to acidic organelles, and Ca2+ released from ER through IP3Rs and RyRs 
could stimulate the NAADP pathway, thus amplifying acidic Ca2+ store signalling. The authors 
proposed that Ca2+ released from ER could activate the NAADP pathway in two ways: first, by 
promoting Ca2+-dependent NAADP synthesis; second, by activating NAADP-sensitive 
channels on lysosomal stores (Morgan A.J. et al., 2013).   
An intimate association between ER and acidic organelles involving Ca2+ microdomains 
has been described in different types of mammalian cells. In particular, in pulmonary artery 
myocytes it has been found that lysosomes were in close apposition with the sarcoplasmic 
reticulum (SR), a specialized type of smooth ER found in myocytes. Interestingly, this coupling 
was able to trigger intracellular Ca2+ signalling involving both the compartments (Kinnear N.P. 
et al., 2008). Furthermore, in 2013 Kilpatrick et al. demonstrated the existence of extensive 
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MCSs between lysosomes and ER also in human fibroblasts (Kilpatrick B.S. et al., 2013). These 
MCSs were similar to those observed between ER and mitochondria, important for Ca2+ 
dialogue between the two compartments (Csordás G. et al., 2006). The authors suggested a 
functional role for this physical coupling, since they found that Ca2+ mobilization from 
lysosomes was able to induce complex Ca2+ signals within the cell involving Ca2+ release from 
ER, probably via IP3Rs. This finding was consistent with the trigger hypothesis for NAADP 
action (Kilpatrick B.S. et al., 2013).  
 
 
 
 
 
 
 
 
 
 
 
Fig.11 - Physical association between lysosomal and ER membranes in human fibroblasts. (A,B) 
Electron micrographs of human fibroblasts pulsed with horseradish peroxidase (A) or BSA-gold (B) to 
label lysosomes. Membrane contact sites (MCSs) between lysosomes and ER are indicated by black 
arrows. Fibres connecting opposing membranes (white arrows) and regions of very close membrane 
apposition (arrowhead) are also indicated. Scale bar: 200 nm (modified from Kilpatrick B.S. et al., 2013). 
 
In 2016 the same research group has demonstrated that, contrary to the prevailing view, 
also the activation of the endogenous TRPML1 was able to trigger a global Ca2+ signalling in 
human cells, in a manner similar to the activation of TPCs by NAADP. Indeed, upon stimulation 
with synthetic agonists, Ca2+ release through TRPML1 was followed by Ca2+ release from the 
ER. These results suggested that TRPML1, like other endo-lysosomal Ca2+ channels, could 
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“chatter” with ER Ca2+ channels to evoke global Ca2+ signals (Kilpatrick B.S. et al., 2016b). 
Moreover, very recently Aston et al. have demonstrated that in rabbit ventricular 
cardiomyocytes lysosomes were intimately associated with the SR, forming microdomains 
which allowed functional Ca2+ signalling between the two organelles. Indeed, they found that 
Ca2+ release from acidic stores subsequently triggered Ca2+ release from SR (Aston D. et al., 
2017).  
 
1.6  Lysosomal Ca2+ dysfunction in neurodegeneration  
Several neurodegenerative diseases, including some lysosomal storage disorders 
(LSDs) and aging-related diseases, have been recently associated with alterations in lysosomal 
Ca2+ handling. LSDs are a heterogeneous group of approximately 50 childhood rare disorders, 
most of which characterized by neurodegeneration. A common feature of these diseases is the 
accumulation (storage) of different types of undegraded macromolecules in the late 
endocytic/lysosomal system (Morgan A.J. et al., 2011). So far, three LSDs have been associated 
with defects in lysosomal Ca2+ homeostasis: Niemann-Pick type C (NPC) disease (Lloyd-Evans 
E. et al., 2008), juvenile neuronal ceroid lipofuscinosis (JNCL, also known as Batten disease) 
(Chandrachud U. et al., 2015), and Chediak-Higashi syndrome (CHS) (Lloyd-Evans E. and 
Platt F.M., 2011). NPC is the first human disease that has been correlated with a dysregulation 
in lysosomal Ca2+ homeostasis. In this disorder, lysosomes accumulate cholesterol, 
sphingomyelin, glycosphingolipids, and sphingosine. The disease is also characterized by low 
Ca2+ levels in the acidic stores, caused by defective lysosomal Ca2+ uptake and subsequent 
reduction in lysosomal Ca2+ release. In NPC the dysfunction in lysosomal Ca2+ leads to an 
impairment in late endosomes/lysosomes fusion and to a defective lipid trafficking (Lloyd-
Evans E. et al., 2008; Lloyd-Evans E. and Platt F.M., 2011). JNCL is characterized by the 
accumulation of autofluorescent lipofuscin in lysosomes and by abnormalities in the production 
and clearance of autophagic vacuoles (Lloyd-Evans E. et al., 2016b). Recent studies have 
46 
 
shown that in cerebellar cells from CLN3ex7/8/ ex7/8 mouse, an animal model recapitulating the 
major genetic defects observed in JNCL patients, there was an elevation in lysosomal Ca2+ 
levels (Chandrachud U. et al., 2015; Lloyd-Evans E. et al., 2016b). Moreover, in CHS, an 
increase in lysosomal Ca2+ uptake seems to be responsible for an impairment in lysosomal 
exocytosis (Styrt B. et al., 1988; Lloyd-Evans E. and Platt F.M., 2011). 
Defects in lysosomal Ca2+ homeostasis have also been described in other common 
neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD). 
In particular, in a mouse model of familial AD (FAD), loss-of-function mutations in presenilins 
(PSEN-/-) significantly altered lysosomal Ca2+ storage and release, especially in hippocampal 
neurons; as a consequence, lysosomal fusion processes were strongly impaired (Coen K. et al., 
2012). It has been proposed that the dysfunction in lysosomal Ca2+ observed in PSEN1-/- cells 
was dependent on the elevation in lysosomal pH, which caused an abnormal Ca2+ efflux from 
lysosomes via the hyperactivation of the lysosomal channel TRPML1 (Lee J.H. et al., 2015). 
Moreover, increasing evidences demonstrated that deregulated Ca2+ signaling and 
lysosomal dysfunction also underlie the neurodegeneration associated to PD. In particular, 
mutations in PD-linked genes GBA1 (encoding for the lysosomal enzyme glucocerebrosidase) 
and LRRK2 (encoding for a protein whose function is still unknown) are responsible for defects 
in lysosomal Ca2+ homeostasis. It has been shown that GBA1 fibroblasts contained lower 
lysosomal Ca2+ levels compared to wild-type cells; in addition, they were characterized by a 
disrupted endo-lysosomal morphology with enlarged and clustered lysosomes. LRRK2 
mutations have been reported to induce hyperactive lysosomal Ca2+ signaling and extensive 
lysosomal morphology defects; moreover, it has been proposed that these mutations could be 
associated with a reduction in lysosomal Ca2+ concentration (Kilpatrick B.S. et al., 2016a). 
At present, there is no information about the possible contribution of lysosomal Ca2+ in 
the neurodegeneration associated to brain ischemia. 
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1.7  Brain ischemia 
Stroke is a multifactorial neurological disease which accounts for ~9% of all death 
around the world and represents the second most common cause of death after ischemic heart 
disease and the major cause of long-lasting disability worldwide. Because of the ageing of 
population, the burden of this neurological disease will increase greatly during the next years, 
especially in the developing countries (Donnan G.A. et al., 2008).  
Several neurological defects occur following stroke, including hemiplegia, numbness, 
balance problems, loss of sensory and vibratory sensation, decreased reflexes, ptosis, visual 
field defects, aphasia, and apraxia due to neuronal damage. However, the severity of symptoms 
depends on the brain area affected by the insult (Pandya R.S. et al., 2011; Chen Y. et al., 2014). 
There are two main types of stroke: ischemic stroke (also known as brain ischemia, 
~85% of cases), resulting from the occlusion of a blood vessel that supplies the brain produced 
by thrombosis or embolism, and haemorrhagic stroke (~15% of cases), due to the rupture of a 
cerebral blood vessel (Donnan G.A. et al., 2008; Pandya R.S. et al., 2011). In ischemic stroke 
the interruption of the blood flow in a portion of the brain cuts off the supply of oxygen and 
nutrients (and in particular glucose) essential for the normal cerebral functions, thus causing 
damage to the brain tissue. After the ischemic insult, a complex sequence of pathological events 
takes place, including disruption of the blood-brain barrier (BBB), energy failure, dysregulation 
of ion homeostasis (and in particular, increased intracellular Ca2+ levels), acidosis, 
excitotoxicity, free-radical mediated toxicity, generation of arachidonic acid products, 
cytokine-mediated apoptosis, activation of glial cells, and infiltration of leukocytes (Arumugam 
T.V. et al., 2009).   
Moreover, ischemic stroke can be categorized into two types, based on the origin of the 
occlusion and the extent of the injured area: global or focal cerebral ischemia. Global cerebral 
ischemia occurs when cerebral blood flow is reduced throughout most or all the brain. This may 
be the result of generalized blood flow reduction secondary to severe physiological 
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derangements, such as persistent hypotension or severe cardiovascular abnormalities. In 
contrast, in focal ischemia the reduction of blood flow occurs in a specific and restricted brain 
region (Traystman R.J., 2003; Zhou Z.B. et al., 2016). During focal brain ischemia two different 
areas are distinguishable in the injured brain: the ischemic “core” and “penumbra”. The core is 
the area of the brain where blood flow is reduced below 10-20% of its normal level; in this area, 
rapid anoxic depolarization causes loss of membrane potential followed by cellular swelling, 
loss of membrane integrity and rapid necrotic cell death (Arumugam T.V. et al., 2009). Due to 
these pathological events, the infarction core results irreversibly damaged (Donnan G.A. et al., 
2008). The penumbra is the tissue surrounding the core, where the blood flow is partially 
preserved due to collateral circulation and diffusion (Arumugam T.V. et al., 2009). Cerebral 
tissue in this area is functionally impaired, but structurally intact, thus a prompt therapeutic 
intervention can promote neurological improvement and recovery. Within this tissue, the 
reduction in blood flow and the resulting loss of oxygen supply trigger a cascade of 
neurochemical events beginning with energy depletion (Donnan G.A. et al., 2008). In 
particular, the combination of ATP reduction and the compensatory activation of anaerobic 
glycolysis leads to an increase in the level of inorganic phosphate, lactate, and H+, thus resulting 
in cellular acidification. The decrease in ATP levels also impairs the ability of membrane 
ATPases to remove Na+ and Ca2+ from the cell, thus causing membrane depolarization, which 
in turn promotes the activation of synaptic glutamate receptors. Since during ischemia the 
energy-dependent mechanisms responsible for glutamate re-uptake are impaired, extracellular 
glutamate accumulates, thus activating glutamate receptors in a prolonged and excessive 
manner. The effect is a massive Ca2+ influx through NMDA (N-methyl-D-aspartate) receptors, 
AMPA (a-amino-3-hydroxy-5-methyl-4-isoxazolepropionate) receptors, and voltage-
dependent Ca2+ channels. Moreover, energy failure and disruption of intracellular Ca2+ 
homeostasis are responsible for mitochondrial impairment. Increased production of free 
radicals, which damage cellular proteins, DNA, and membrane lipids, results from 
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mitochondrial dysfunction, Ca2+ overload, and activation of enzymes such as cyclooxygenase, 
and nitric oxide synthase. Ca2+ influx induces the activation of two different cysteine proteases: 
caspases and calpains. These, in turn, cause the degradation of cytoskeletal proteins, membrane 
receptors, and metabolic enzymes. Moreover, the increase in intracellular Na+ levels can 
directly cause cell swelling, oxidative stress, and cell death. When intracellular Na+, Cl-, and 
H2O levels increase at the same time, cytotoxic edema occurs. Moreover, excessive K
+ efflux 
and intracellular K+ depletion play a role in apoptotic cascade, whereas K+ released from 
mitochondria contributes to increased reactive oxygen species (ROS) production and ATP 
depletion. Oxidative stress and caspases activation exacerbate mitochondrial dysfunction that 
eventually results in apoptotic cell death (Arumugam T.V. et al., 2009).   
 
 
 
 
 
 
 
 
 
 
Fig.12 - Pathogenic events dysregulating ionic homeostasis during brain ischemia. Energy depletion 
occurring during brain ischemia is followed by a cascade of pathological events, including the disruption 
of ionic homeostasis, Ca2+ channel dysfunction, membrane disruption, formation of a cytotoxic edema, 
protein degradation, oxidative stress, and mitochondrial dysfunction. The combination of all these 
events ultimately lead to apoptotic neuronal death (modified from Arumugam T.V. et al., 2009). 
 
Moreover, upon reperfusion, when the occlusion is removed (spontaneously or 
pharmacologically) and the blood flow is restored in the infarcted area, oxygen availability 
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results in a larger increase in ROS and nitric oxide (NO) production, which add up to free 
radicals produced during ischemia. The resulting oxidative stress causes further neuronal 
damage and may ultimately result in the initiation of pathways that lead to necrotic and 
apoptotic cell death (Manzanero S. et al., 2013).  
In addition to mitochondria, cerebral ischemia also induces dysfunctions in the ER. 
Indeed, an increase in the expression of genes encoding ER stress proteins (Paschen W. et al., 
2003; Shibata M. et al., 2003; Paschen W. and Mengersdorf T., 2005; Pallast S. et al., 2010) 
and a marked depletion of Ca2+ ions from ER have been observed in cortical neurons after 
exposure to oxygen and glucose deprivation (OGD) followed by reoxygenation (Sirabella R. et 
al., 2009), an in vitro model to reproduce the pathological events occurring during 
ischemia/reperfusion.  
 
1.7.1  Brain ischemia and ER dysfunction  
Besides Ca2+ storage and signalling, a central function of the ER is the folding and 
processing of newly synthesized proteins, two Ca2+-dependent processes. When these functions 
are impaired, misfolded and unfolded proteins accumulate in the ER lumen, thus leading to a 
pathological condition termed “ER stress”. To cope with conditions associated with ER 
impairment, functioning cells activate a high conserved stress response termed “Unfolded 
Protein Response” (UPR), in an attempt to restore ER functions and assist the correct protein 
folding. Various proteins play a role in this critical process, including the ER molecular 
chaperone GRP78 (glucose-regulated protein 78 kDa). Indeed, the main purpose of UPR is to 
increase protein folding and processing capacity, thus reducing the load of misfolded proteins 
in ER lumen. However, when ER stress is too severe and prolonged, apoptotic cell death is 
triggered (Paschen W. and Mengersdorf T., 2005; Malhotra J.D. and Kaufman R.J., 2007).  
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Several experimental evidences showed that ER stress plays a key role in the 
neurodegeneration associated to brain ischemia. Indeed, it has been reported that the ischemic 
insult induces the accumulation of misfolded proteins in ER lumen and promotes the expression 
of several genes involved in ER stress (Paschen W. and Mengersdorf T., 2005; Kim I. et al., 
2008). Moreover, reperfusion of the affected tissues triggers oxidative stress, with production 
of NO, a mediator of protein nitrosylation, and ROS that alter cellular redox-dependent 
reactions, interfere with protein disulphide bonding, and result in protein misfolding. NO and 
other reactive molecules may also modify oxidizable residues (cysteine and tyrosine) in ER 
calcium channels, including RyRs (S-nitrosylation) and SR/ER Ca2+-ATPases (SERCAs) (by 
tyrosine nitration), thus causing ER Ca2+ depletion and, consequently, exacerbating protein 
misfolding (Kim I. et al., 2008).   
 
1.7.2  Brain ischemia and autophagy 
Recently, the role of autophagy in the neurodegeneration associated to cerebral ischemia 
has been extensively investigated. Several studies have reported that autophagy is activated 
following the ischemic insult; however, the contribution of this process to neuronal 
death/survival is still a matter of debate (Chen W. et al., 2014). Newly emerged research 
indicates that altered autophagy flux functionality is involved in the neurodegeneration of the 
aging brain, chronic neurological disease, and after acute ischemic brain injury. However, 
currently there is no unified theory on the role played by autophagy in brain ischemia, and 
increasing evidence demonstrated that the process is a double-edged sword in this neurological 
disease (Chen W. et al., 2014; Yin Y. et al., 2017). At present the controversial role of 
autophagy during ischemia is prevalent across the literature: indeed, some studies conclude that 
autophagy is neuroprotective and other studies suggest that autophagy leads to cell death. In 
example, Carloni et al. reported a study of ischemia in rats, in which the inhibition of autophagy 
by 3-MA (3-methyladenine) led to a decrease in beclin 1 expression and to increased cell death; 
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however, they found that the promotion of autophagy by rapamycin reduced cell death and 
brain injury, suggesting a beneficial role for autophagy (Carloni S. et al., 2010). Conversely, 
other studies have shown that autophagy is neurotoxic, since it leads to cell death after ischemia. 
In example, in their study Wen et al. demonstrated profound activation of autophagy in rats 
subjected to permanent middle cerebral artery occlusion (pMCAO) (Wen Y.D. et al., 2008); 
moreover, the administration of the autophagy inhibitor 3-MA was neuroprotective and 
prevented neuronal death after ischemia induced in rats by pMCAO and four-vessel occlusion 
(4-VO) (Wen Y.D. et al., 2008; Xin X.Y. et al., 2011).  
Since at present the exact role and the molecular mechanisms of autophagy process 
during brain ischemia have not yet been elucidated, further studied are required to verify the 
contribution of this process to the pathophysiological events underlying this neurological 
disorder.  
 
1.7.3  Pharmacological treatments for brain ischemia 
So far, two main approaches have emerged for acute treatment of ischemic stroke. The 
first strategy targets the insult itself, trying to rapidly restore focal cerebral blood flow by lysing 
or mechanically removing the arterial thrombus. The second major therapeutic approach 
involves neuroprotection, which aims to interrupt the cascade of pathophysiological events 
leading to cell death, thus reducing the vulnerability of the penumbra (Brouns R. and De Deyn 
P.P., 2009).  
At present, the only effective pharmacological treatment for acute ischemic stroke 
approved by the Food and Drug Administration (FDA) and the European Medicines Agency 
(EMA) is the early intravenous administration of recombinant tissue plasminogen activator 
(tPA) (Donnan G.A. et al., 2008; Brouns R. and De Deyn P.P., 2009; Haelewyn B. et al., 2010). 
This thrombolytic drug is a serine protease that converts the proenzyme plasminogen to the 
protease plasmin, which is responsible for the degradation of the thrombus (Haelewyn B. et al., 
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2010). However, because of its short therapeutic time window (between 3 and 4.5 hours after 
stroke onset) and the adverse effect of intracerebral haemorrhage (6-7% of cases), the number 
of patients who might receive treatment and therefore potential benefit is small (Donnan G.A. 
et al., 2008; Hacke W. et al., 2008; Brouns R. and De Deyn P.P., 2009). In the last decades 
many drugs have been tested to reduce brain damage following brain ischemia in animal 
models, but most of them have failed to reach clinical trials or to be efficient in ischemic stroke 
patients (Haelewyn B. et al., 2010). In particular, the number of studies involving 
neuroprotective treatments has increased exponentially since elucidation of the molecular 
mechanisms of stroke in the 1970s. Although the great number of preclinical and clinical studies 
have further improved the understanding of the pathophysiological mechanisms underlying 
ischemic stroke, great challenges remain in identifying agents with significant therapeutic 
efficacy.  
Figure 13 summarizes some neuroprotective therapeutic approaches that have been 
evaluated in a variety of preclinical or clinical trials. These strategies include the administration 
of voltage-gated Ca2+ channels inhibitors, a number of NMDA and AMPA receptors inhibitors 
to reduce glutamate excitotoxicity, -aminobutyric acid (GABA) agonists, antioxidant agents, 
inhibitors of nitric oxide synthesis, and immunoregulators. However, all these drugs failed to 
reach the market, since they showed no or limited therapeutic benefits for patients (Karsy M. et 
al., 2017; Rajah G.B. and Ding Y., 2017). Thus, the further investigation of additional 
molecular mechanisms underlying the pathogenesis of brain ischemia is needed for the 
development of novel and more efficacious pharmacological tools able to prevent, or at least 
limit, the devastating consequences of this widespread neurological disorder.  
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Fig.13 - Pathophysiology of ischemic stroke and neuroprotective strategies. The basic underlying 
pathology of ischemic stroke involves excitotoxicity and failure of cellular homeostatic functions, 
resulting in upregulation of Ca2+ and overproduction of free radicals. The end result involves cellular 
demise, maladaptive genetic expression, altered proteolysis, lipid peroxidation, recruitment of immune 
cells, and further inflammatory cascades. A variety of neuroprotective approaches (shown in red) have 
been tested in an attempt to target these various aspects (modified from Karsy M. et al., 2017). 
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2. AIM OF THE STUDY  
Recent studies have demonstrated that a physical interaction between lysosomes and the 
endoplasmic reticulum (ER) occurs in different cell types under physiological conditions 
(Kilpatrick B.S. et al., 2013; Kilpatrick B.S. et al., 2016b; Aston D. et al., 2017). Moreover, it 
has been shown that the tight apposition between the two compartments plays an important 
functional role, since these intracellular Ca2+-storing organelles could communicate with the 
aim to regulate intracellular Ca2+ homeostasis, under both physiological and pathological 
conditions (Patel S. and Docampo R., 2010; Morgan A.J. et al., 2011). This interaction has been 
well characterized in sea urchin eggs (Morgan A.J. et al., 2013), human fibroblasts (Kilpatrick 
B.S. et al., 2013; Kilpatrick B.S. et al., 2016b), and rabbit ventricular cardiomyocytes (Aston 
D. et al., 2017). However, the functional coupling between lysosomes and ER has not yet been 
properly investigated in the central nervous system (CNS). Furthermore, our research group has 
already shown that ER Ca2+ homeostasis is highly compromised under hypoxic conditions; this 
dysfunction occurs at neuronal level and leads to the activation of the ER stress pathway, thus 
triggering neuronal death (Sirabella R. et al., 2009). 
Considering these evidences, my thesis work has been focused on the study of the 
functional coupling between lysosomes and ER in primary cortical neurons under physiological 
conditions and under hypoxic conditions mimicking brain ischemia.  
The first aim of my study has been to establish the possible contribution of the main 
lysosomal Ca2+ channel, TRPML1, in the regulation of lysosomal and ER Ca2+ homeostasis 
under physiological conditions. We started from the evidence that this channel can “chatter” 
with ER Ca2+ channels to trigger global Ca2+ signals in human fibroblasts (Kilpatrick B.S. et 
al., 2016b).   
Then, we evaluated the existence of a crosstalk between lysosomes and ER in anoxic 
neurons and the possible contribution of TRPML1 in this phenomenon. In order to reproduce 
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an in vitro model of brain ischemia, cortical neurons were exposed to 3 hours of oxygen and 
glucose deprivation (OGD) followed by 24 hours of reoxygenation; this model recapitulates the 
pathological events occurring during brain ischemia. In these cells, we analyzed the expression 
levels of TRPML1 during anoxia and the possible repercussion of the pharmacological 
modulation of the channel on neuronal survival and on the maintenance of lysosomal and ER 
Ca2+ homeostasis.  
Since it has been reported that ER stress and apoptotic cell death play a key role in the 
neurodegeneration associated to brain ischemia (Paschen W. and Mengersdorf T., 2005), we 
also investigated the effect of TRPML1 modulation on the expression of some markers involved 
in the Unfolded Protein Response (UPR) and in the apoptotic cell death.  
Finally, we also studied the possible effect of TRPML1 modulation during anoxia on the 
autophagic pathway, whose role is controversial in hypoxic conditions. We started from the 
evidence that Ca2+ released through this channel is able to activate the autophagic flux (Medina 
D.L. et al., 2015; Zhang X. et al., 2016). 
To these aims, we performed some biochemical and functional experiments on cortical 
neurons under physiological conditions or in neurons exposed to oxygen and glucose 
deprivation followed by reoxygenation, by using some pharmacological and genetic tools able 
to modulate TRPML1 expression or function. Moreover, we also tested the effect of TRPML1 
pharmacological modulation in an in vivo model of brain ischemia represented by rats subjected 
to the transient occlusion of the middle cerebral artery (tMCAO). Our conclusions seem to favor 
a detrimental role for autophagy in our experimental models of brain ischemia. 
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3. MATERIALS AND METHODS 
3.1 Reagents and molecular structures of the pharmacological tools used 
in the present study  
Media and sera for cell cultures were purchased from Life Technologies (Milan, Italy); 
antibiotics for cell cultures were from Sigma-Aldrich (Milan, Italy). Rabbit polyclonal 
antibodies against TRPML1 (#ACC-081) and STIM1 (STIM1-ATTO-550, #ACC-063-AO) 
were from Alomone Labs (Jerusalem, Israel); mouse monoclonal antibody against -tubulin 
(#T5168), and rabbit polyclonal antibody against LAMP2 (#L0668) were from Sigma-Aldrich 
(Milan, Italy); mouse monoclonal antibody against STIM1 (#sc-166840) was from Santa Cruz 
Biotechnology, Inc. (Dallas, TX, USA); mouse monoclonal antibody against IP3R-3 (#610313) 
was from BD Biosciences (San Jose, CA, USA); rabbit polyclonal antibody against LAMP1 
(#AB2971) was from Merck Millipore (Darmstadt, Germany); rabbit polyclonal anti-GRP78 
(#3183) antibody was from Cell Signaling Technology, Inc. (Danvers, MA, USA); rabbit 
polyclonal antibodies against beclin 1 (#NB500-249) and p62 (#NBP1-48320) were from 
Novus Biologicals (Littleton, CO, USA); rabbit polyclonal antibodies against caspase 9 
(#GTX132331) and LC3B (#GTX127375) were from GeneTex Inc. (Irvine, CA, USA). ECL 
reagents and all chemicals for Western blotting were from GE Healthcare (Milan, Italy). Small 
interfering RNAs (siRNAs) against TRPML1 and siRNA-Control were purchased from Qiagen 
(Milan, Italy). (1R,3S)-1-[3-[[4-(2-Fluorophenyl)piperazin-1-yl]methyl]-4-methoxyphenyl]-
2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid (trans-Ned19) was from Tocris 
Bioscience (Bio-Techne/R&D Systems, Minneapolis, MN, USA); 2-(2-Oxo-2-(2,2,4-
trimethyl-3,4-dihydroquinolin-1(2H)-yl)ethyl)isoindoline-1,3-dione (ML-SA1) was from 
Merck Millipore (Darmstadt, Germany), while Gly-Phe β-naphthylamide (GPN) and 
YM201636 were purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). 
Thapsigargin and bafilomycin A1 were from Sigma-Aldrich (Milan, Italy). 1-[2-(5-
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Carboxyoxazol-2-yl)-6-aminobenzofuran-5-oxy]-2-(21-amino-51-methylphenoxy)-ethane-
N,N,N1,N1-tetraacetic acid penta-acetoxymethyl ester (Fura-2/AM) was from Molecular 
Probes (Invitrogen, Milan, Italy).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2 - Pharmacological tools used in this study. 
 
3.2 Primary cultures of rat cortical neurons 
Cortical neurons-enriched cultures were obtained from brains of 14/16-day-old Wistar 
rat embryos (Charles River). Briefly, rats were first anesthetized and then decapitated to 
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minimize pain and distress. Dissection and dissociation were performed in Ca2+/Mg2+-free PBS 
(Phosphate-Buffered Saline) containing glucose (30 mM). Tissues were incubated with papain 
for 10 minutes at 37°C and dissociated by trituration in Earle's Balanced Salt Solution (EBSS) 
containing DNase (0,16 U/ml), bovine serum albumin (BSA) (10 mg/ml), and ovomucoid (10 
mg/ml). Cells were plated at 15×106 in 100 mm plastic Petri dishes or on glass coverslips 
precoated with poly-D-lysine (20 μg/ml) in minimum Eagle's medium/F12 containing glucose, 
5% fetal bovine serum (FBS), 5% horse serum (HS), glutamine (2 mmol/l), penicillin (50 U/ml), 
and streptomycin (5 g/ml). Neurons were cultured at 37°C in a humidified 5% CO2 atmosphere 
and used after 7 days of culture. Ara-C (cytosine arabinoside, 10 μM) was added within 72 
hours of plating to prevent non-neuronal cell growth. All the experiments were performed 
according to the procedures described in the experimental protocols approved by the Ethical 
Committee of “Federico II” University of Naples, Italy. 
 
3.3 Animal care 
Male Sprague-Dawley rats (Charles River), weighting 200 g to 250 g, were housed 
under diurnal lighting conditions (12 hours darkness/light) and in a conditioned room (23°C). 
Experiments were performed according to the international guidelines for animal research and 
approved by the Animal Care Committee of “Federico II” University of Naples, Italy. To 
minimize suffering, animals, during any surgical or invasive procedure, were anesthetized using 
2% sevofluorane, 60% N2O, and 38% O2, and the rectal temperature was maintained at 
37±0.5°C with a heat-controlled mat (Harvard Apparatus).  
 
3.4 Immunocytochemistry and confocal microscopy  
Cortical neurons were rinsed twice in cold 0.01 M PBS at pH 7.4 and fixed in 4% 
paraformaldehyde for 20 minutes at room temperature. After three washes in PBS, cells were 
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blocked in PBS containing 3% BSA for 30 minutes and then incubated overnight at 4°C with 
anti-TRPML1 antibody (1:1000) (for experiments presented in Fig.14 A), or with anti-
TRPML1 (1:1000) and anti-STIM1-ATTO-550 (1:400) antibodies (for experiments presented 
in Fig.19). Then, cells were washed with PBS and incubated with anti-rabbit Cy3-conjugated 
antibody (Jackson, 1:200) (for experiments presented in Fig.14 A), or with anti-rabbit Cy2-
conjugated antibody (Jackson, 1:200) (for experiments presented in Fig.19) for 1 hour at room 
temperature under dark conditions and washed again with PBS. To allow visualization of cell 
nuclei in the fluorescent staining, cells were finally incubated for 5 minutes with Hoechst 1 M. 
Finally, cover glasses were mounted with a SlowFadeTM Antifade Kit (Molecular Probes, 
Invitrogen) and acquired by a 63X oil immersion objective using a Zeiss inverted 700 confocal 
microscope (Scorziello A. et al., 2013). Quantitative analysis of co-localization of TRPML1 
and STIM1-ATTO-550 (Fig.19) was conducted by using the co-localization plug-in JACoP 
(Just Another Colocalization Plugin) for ImageJ Software (NIH, Bethesda, MA, USA) (Bolte 
S. and Cordelières F.P., 2006). A correlation of signal intensity was calculated as a Pearson’s 
coefficient (Rr). Rr is a quantitative measurement that estimates the degree of overlap between 
the fluorescence signals obtained from two channels. 
 
3.5 Small interfering RNAs 
TRPML1 knocking down was achieved by using three different FlexiTube small 
interfering RNAs (siRNAs) against the channel (Qiagen, Milan, Italy). Neurons were 
transfected in OptiMem medium by HiPerFect Transfection Reagent (Qiagen, Milan, Italy) 
with the non-targeting control and the following siRNAs (all at 10 nM): 
(#1) Rn_LOC288371_4 (sense strand: 5’-GCAGAACGAGUUUGUUGUATT-3’; antisense 
strand: 5’-UACAACAAACUCGUUCUGCAG-3’); 
(#2) Rn_LOC288371_3 (sense strand: 5’-UGAUCACAUUUGACAAUAATT-3’; antisense 
strand: 5’UUAUUGUCAAAUGUGAUCAGG-3’);  
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(#3) Rn_LOC288371_2 (sense strand: 5’-ACGAGAUCCCUGACUGUUATT-3’; antisense 
strand: 5’-UAACAGUCAGGGAUCUCGUTG-3’).  
The mixture containing the specific siRNA was added to cells and then, after 5 hours of 
incubation, the medium was replaced with fresh medium. 
 
3.6 Western blotting 
After treatments, cells were washed in PBS and collected by gentle scraping in ice-cold 
lysis buffer containing 20 mM Tris-HCl (pH 7.5), 10 mM NaF, 1 mM PMSF, 1% Nonidet P-
40, 1 mM Na3VO4, 0.1% aprotinin, 0.7 mg/ml pepstatin and 1 μg/ml leupeptin. After 
centrifugation (12,000 rpm, 30 minutes, 4°C), the supernatants were collected and protein 
concentration was determined by the Bradford method (Bradford M.M., 1976). Proteins (20 μg) 
were loaded and separated on 10% sodium dodecyl sulphate (SDS)-polyacrylamide gels for 
TRPML1, LAMP1, LAMP2, beclin 1, p62, GRP78, and caspase 9 expression, and on 15% 
SDS-polyacrylamide gels for LC3 expression, and then transferred onto Hybond ECL 
nitrocellulose membranes (GE Healthcare, Milan, Italy). The membranes were blocked for 1 
hour at room temperature with 5% non-fat dry milk (Bio-Rad, Milan, Italy) in Tris-Buffered 
Saline-TWEEN 20 (2 mM Tris-HCl, 50 mM NaCl, pH 7.5, plus 0.1% TWEEN 20), and then 
incubated overnight at 4°C in the blocking buffer containing the polyclonal antibodies against: 
TRPML1 (1:1000), LAMP1 (1:1000), LAMP2 (1:1000), beclin 1 (1:1000), p62 (1:1000), LC3 
(1:1000), GRP78 (1:1000) or caspase 9 (1:1000). All membranes were re-blotted in the 
blocking buffer with the monoclonal antibody against -tubulin (1:2000). Immunoreactive 
bands were detected using ECL reagent kits. The optical density of the bands, normalized to -
tubulin, was determined by a Chemi-Doc Imaging System (Bio-Rad, Hercules, CA, USA). 
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3.7 [Ca2+]i measurements  
[Ca2+]i was measured by single-cell computer assisted video imaging (Secondo A. et al., 
2007). Briefly, neuronal cells plated on glass coverslips were loaded with 10 μM Fura-2/AM 
for 1 hour at 37°C in cell culture medium or in Normal Krebs solution containing 5.5 mM KCl, 
160 mM NaCl, 1.2 mM MgCl2, 1.5 mM CaCl2, 10 mM glucose, and 10 mM HEPES-NaOH 
(pH 7.4). At the end of the Fura-2/AM loading period, coverslips were placed into a perfusion 
chamber (Medical System, Co. Greenvale, NY, USA) mounted onto a Zeiss Axiovert 200 
microscope (Carl Zeiss, Zena, Germany) equipped with a FLUAR 40X oil objective lens. The 
experiments were carried out with a digital imaging system composed of MicroMax 512BFT 
cooled CCD camera (Princeton Instruments, Trenton, NJ, USA), LAMBDA 10-2 filter wheeler 
(Sutter Instruments, Novato, CA, USA) and Meta-Morph/MetaFluor Imaging System software 
(Universal Imaging, West Chester, PA, USA). All the results are presented as cytosolic Ca2+ 
concentration. Assuming that the Kd for Fura-2 was 224 nM, the equation of Grynkiewicz et 
al. (Grynkiewicz G. et al., 1985; Urbanczyk J. et al., 2006) was used for calibration.  
 
3.8 Determination of mitochondrial function 
Neuronal survival was assessed by the 3[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-
tetrazolium bromide (MTT) assay. The assay is based on the red-ox ability of living 
mitochondria to convert dissolved MTT into insoluble formazan. Briefly, after treatments, cells 
were incubated in 1 ml of MTT solution (0.5 mg/ml) for 1 hour at 37°C. To stop incubation, 
MTT solution was removed and 1 ml of dimethyl sulfoxide (DMSO) was added to solubilize 
the formazan product. The absorbance was monitored at 540 nm with a Perkin-Elmer LS 55 
luminescence spectrometer (Perkin-Elmer Ltd, Beaconsfield, England). The data were 
expressed as a percentage of cell viability compared to control cultures.  
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3.9 Immunoprecipitation (IP) 
Cells were homogenized in a lysis buffer containing 50 mM HEPES, 100 mM NaCl, 1.5 
mM MgCl2, 1 mM PMSF, 0.2% Nonidet P-40, 5 μg/ml aprotinin, 10 μg/ml leupeptin, and 2 
μg/ml pepstatin. Lysates were cleared by centrifugation (12,000 rpm, 30 minutes, 4°C). 500 g 
of cell lysate were immunoprecipitated with anti-STIM1 (1:200), anti-TRPML1 (1:200), anti-
IP3R-3 (1:200), or anti-LAMP1 (1:200) antibodies. Then the immunoprecipitated samples were 
resolved by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and 
transferred onto a nitrocellulose membrane. Immunoblot analysis was performed using anti-
TRPML1 (1:1000), anti-STIM1 (1:1000), or anti-LC3 (1:1000) antibodies. 
 
3.10 Combined oxygen and glucose deprivation (OGD) 
Anoxic conditions were reproduced in vitro by exposing cortical neurons to 3 hours of 
oxygen and glucose deprivation (OGD) followed by 24 hours of reoxygenation (Rx). In 
particular, OGD was achieved by incubating neurons for 3 hours in a glucose-free medium 
previously saturated with 95% N2 and 5% CO2 for 20 minutes and containing 116 mM NaCl, 
5.4 mM KCl, 0.8 mM MgSO4, 26.2 mM NaHCO3, 1 mM NaH2PO4, 1.8 mM CaCl2, 0.01 mM 
glycine and 0.001% phenol red (Goldberg M.P. and Choi D.W., 1990). Hypoxic conditions 
were maintained using a hypoxic chamber (atmosphere 5% CO2 and 95% N2, temperature 
37°C). At the end of incubation, OGD was stopped by replacing the glucose-free medium with 
a culture medium containing normal levels of O2 and glucose; thus, reoxygenation was achieved 
by returning neurons to normoxic conditions (5% CO2 and 95% air, temperature 37°C) for 24 
hours. For the experiments of Fig.20 B, also cortical glial cells were exposed to OGD/Rx. 
Ischemic preconditioning (IPC) was reproduced by pre-exposing neurons, 24 hours before 
OGD/Rx, which represent the lethal insult, to 30 minutes of OGD, a condition that is 
comparable to a sublethal ischemic insult.  
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3.11 Transient focal ischemia 
Rats were subjected to transient middle cerebral artery occlusion (tMCAO), a surgical 
procedure that consists in the insertion of a suture filament into the internal carotid artery until 
to the middle cerebral artery (MCA) (Longa E.Z. et al., 1989), modified and readapted in our 
laboratory (Pignataro G. et al., 2008). Briefly, under an operating stereomicroscope (Nikon 
SMZ800, Nikon Instruments, Florence, Italy), the first step was the identification and the 
exposition of right carotid bifurcation, by using surgical pincers (Dumont #7, FST). Then, the 
external carotid artery near the bifurcation was cut and electrocauterized to create a stump on 
the artery. A silicon-coated nylon filament (Doccol, Ca, USA) was inserted through the stump 
and was gently advanced 19 mm into the right internal carotid artery until it blocks the origin 
of the MCA. At this point, the surgical wound was temporarily closed by surgical suture and 
the filament left in place for 100 minutes and kept still in place by using a braided silk suture 
(FST). When the time of occlusion was expired, the filament was gently removed in order to 
allow reperfusion. Induction of ischemia was confirmed by monitoring regional cerebral blood 
flow in the area of the right MCA through a disposable microtip fiber optic probe (diameter 0.5 
mm), applied with a cyanoacrylate glue to the right temporo-parietal region of the rat skull, 
connected through a Master Probe to a laser Doppler computerized main unit (PF5001; 
Perimed, Sweden) and analyzed using PSW Perisoft 2.5 (Kawano T. et al., 2006).  
Animals were divided into three groups: (i) sham-operated rats receiving 
intracerebroventricular (icv) infusion of vehicle; (ii) ischemic rats receiving icv infusion of 
vehicle; (iii) ischemic rats receiving icv infusion of trans-Ned19 at the onset of reperfusion. All 
animals were sacrificed 24 hours after tMCAO.  
 
 
 
65 
 
3.12 Intracerebroventricular administration of trans-Ned19 
Drug delivery into brain lateral ventricle was carried out in rats positioned on a 
stereotaxic apparatus at different time points after the induction of transient ischemia (onset, 3 
hours, 6 hours, 12 hours, 24 hours). The drug was intracerebroventricularly (icv) infused 
through a stainless-steel cannula (brain infusion kit alzet® 3-5mm), positioned into the right 
lateral ventricle relating to the following stereotaxic coordinates from the bregma: 0.4 mm 
caudal, 2 mm lateral, and 2 mm below the dura, connected to a Hamilton syringe (10µl). Trans-
Ned19 compound was dissolved in saline solution (NaCl 0,9%) and icv injected once at a 
volume of 5µl.  
 
3.13 Evaluation of the infarct volume 
The ischemic volume was evaluated by 2,3,5-triphenyl tetrazolium chloride (TTC) 
staining. Specifically, 24 hours after starting reperfusion from tMCAO, animals were 
euthanized and the brains were removed. Trans-Ned19 24 hours rats were sacrificed 48 hours 
after the induction of ischemia. After that, brains were cut into 1 mm coronal slices with a 
vibratome (Campden Instrument, 752 M). Coronal slices were incubated in 2% TTC for 20 
minutes and in 4% paraformaldehyde overnight. The infarct area of the sections (about six in 
total) was calculated with image analysis software (Image-J 1.50c) (Bederson J.B. et al., 1986). 
The total infarct volume, corrected for edema, was calculated as sum of the single infarcted 
areas and expressed as percentage of the volume of the hemisphere ipsilateral to the lesion. 
Edema was calculated by difference between the volume of hemisphere ipsilateral to the lesion 
and that of hemisphere contralateral to the lesion.  
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3.14 Evaluation of neurological deficit scores 
Neurological scores were evaluated immediately before the sacrifice, at 24 hours from 
tMCAO, according to 2 scales: a general neurological scale and a focal neurological scale 
(Clark W.M. et al., 1997). In the general score, the following 6 general deficits were measured: 
(1) hair conditions, (2) position of ears, (3) eye conditions, (4) posture, (5) spontaneous activity, 
and (6) epileptic behaviour. For each of the 6 general deficits measured, animals received a 
score ranging between 0 and 12 depending on the severity of signs. The scores of investigated 
items were then summed to provide a total general score ranging from 0 to 28. In the focal 
score, the following 7 areas were assessed: (1) body symmetry, (2) gait, (3) climbing, (4) 
circling behaviour, (5) front limb symmetry, (6) compulsory circling, and (7) whisker response. 
For each of these items, animals were rated between 0 and 4 depending on severity. The 7 items 
were then summed to give a total focal score ranging from 0 to 28. 
 
3.15 Statistical analysis 
Data are expressed as mean ± S.E.M. Statistical analysis was performed ad hoc with 
unpaired t-test or one-way analysis of variance (ANOVA) followed by Newman-Keuls test. 
Statistical significance was accepted at the 95% confidence level (p < 0.05). 
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4. RESULTS AND DISCUSSION 
4.1 Immunocytochemical and biochemical characterization of TRPML1 
expression in rat primary cortical neurons  
Primary cultures of cortical neurons were obtained from brains of E14/E16 rat embryos, 
as described in the Materials and Methods section. By immunocytochemical analysis, we 
showed that the lysosomal Ca2+ channel TRPML1 was expressed at high levels in these cells 
under physiological conditions (Fig.14 A). 
In order to downregulate TRPML1 protein expression, we transfected cortical neurons 
with three different siRNA (small interfering RNA) duplexes targeting TRPML1 mRNA (10 
nM), or with a scrambled siRNA (siControl) (10 nM) as negative control. Then, to determine 
the transfection efficiency and in consideration of the turnover of the protein, TRPML1 protein 
levels were assessed at 24 hours after siRNAs transfection by means of Western blotting 
analysis. The results obtained showed that in our cellular model only siRNA #2 (siTRPML1 
#2) efficiently downregulated TRPML1 protein expression at 24 hours after transfection 
(Fig.14 B). Moreover, to determine the duration of TRPML1 knocking down, we performed 
time-course experiments in which cells were harvested for Western blotting analysis at 24 and 
48 hours after siTRPML1 #2 transfection. Our results indicated that this siRNA was able to 
downregulate TRPML1 expression only at 24 hours after transfection, since within 48 hours 
TRPML1 expression levels tended to increase, returning to the control values (Fig.14 C).  
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Fig.14 - TRPML1 immunolocalization and downregulation in rat primary cortical neurons. (A) 
Immunocytochemical analysis of TRPML1 (red immunosignal) in rat primary cortical neurons; nuclei 
were counterstained with Hoechst (blue). Scale bar: 5 m. (B) Representative quantification of TRPML1 
protein expression in cortical neurons transfected with 3 different siRNAs (10 nM) against TRPML1 
mRNA, or with a non-targeting control (siControl). (C) Representative Western blotting (left) and 
quantification (right) of TRPML1 protein expression after time-course experiments with siTRPML1 #2 
(10 nM) at 24 and 48 hours after transfection.  
All the experiments were repeated 3 times with similar results. *p<0.05 versus siControl. 
 
This observation suggests a rapid turnover rate of TRPML1 at neuronal level. 
Interestingly, our data are in accordance with the results reported by Miedel et al., who showed 
that in HeLa cells repeated siRNA applications were needed to successfully knock down the 
channel over longer periods (Miedel M.T. et al., 2008). 
 
4.2 Pharmacological characterization of TRPML1 activity in cortical 
neurons 
To verify the role of TRPML1 in lysosomal Ca2+ homeostasis in cortical neurons, we 
performed single-cell Fura-2/AM microfluorimetry experiments under physiological 
conditions. In our experiments, Ca2+ efflux from lysosomes was elicited by the administration 
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of ML-SA1 (10 M), a membrane-permeant synthetic chemical which acts as a specific agonist 
of TRPML1 (Shen D. et al., 2012). The results obtained indicated that the pharmacological 
activation of the channel promoted an increase in intracellular Ca2+ concentration ([Ca2+]i) 
through TRPML1 of approximately 40% compared to basal values (Fig.15 A). Conversely, this 
effect was completely abrogated when the channel was silenced with the specific siRNA against 
TRPML1 mRNA (siTRPML1 #2). Considering the absence of response upon ML-SA1 
stimulation in neurons silenced for TRPML1, at the end of this experiment the specific Ca2+ 
ionophore ionomycin (5 M) was used to verify the efficiency of the fluorescent probe Fura-
2/AM and the cell status in our experimental system (Fig.15 B).  
It has been reported that in macrophages an increase in lysosomal pH, induced by the 
incubation with ammonium chloride (NH4Cl) or by the administration of the lysosomal v-
ATPase inhibitor bafilomycin A1, was able to elicit Ca2+ efflux from lysosomes, thus emptying 
lysosomal Ca2+ stores (Christensen K.A. et al., 2002). Moreover, it has been proposed that in 
presenilin 1 knock out cells (PS1KO) a defective lysosomal acidification, due to a v-ATPase 
deficiency, could hyperactivate the lysosomal Ca2+ channel TRPML1, thus promoting an 
abnormal Ca2+ efflux from lysosomes (Lee J.H. et al., 2015). Considering these evidences, we 
verified whether the alkalinization of lysosomal lumen could impair lysosomal Ca2+ 
homeostasis and activate TRPML1 channel in cortical neurons under physiological conditions. 
To this aim, we first analyzed the effect of bafilomycin A1 (100 nM) on lysosomal Ca2+ release 
in these cells. Interestingly, this drug was able to elicit Ca2+ efflux from lysosomes, thus 
inducing an increase in [Ca2+]i of approximately 30% compared to basal values (Fig.15 C). 
Conversely, in neurons transfected with the specific siRNA against the channel this effect was 
totally abolished, thus suggesting that the alkalinization of lysosomal pH promoted Ca2+ efflux 
from lysosomes through TRPML1 (Fig.15 D). However, the concomitant administration of 
both ML-SA1 and bafilomycin A1 provoked the same effect as that observed with ML-SA1 or 
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bafilomycin A1 administered alone, both in cells exposed to control conditions and in cells 
silenced for TRPML1 expression (Fig.15 E).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.15 - Effect of ML-SA1 and bafilomycin A1 on intracellular Ca2+ levels. (A-B) Representative 
traces of the effect of ML-SA1 (10 M) administration on intracellular Ca2+ levels in cortical neurons 
under control conditions (A) and in neurons transfected with the specific siRNA against TRPML1 
mRNA (B). (C-D) Representative traces of the effect of bafilomycin A1 (100 nM) administration in 
cortical neurons under control conditions (C) and in neurons transfected with siTRPML1 #2 (D). (E) 
Bar graph depicts the quantification of the effect of the two pharmacological tools on intracellular Ca2+ 
levels under control conditions (left) and in neurons silenced for TRPML1 expression (right).  
All the experiments were repeated 3 times on almost 40 cells with similar results. 
* p<0.05 versus basal levels; ** p<0.05 versus control. 
 
 
Collectively, these results suggest that TRPML1 plays a critical role in the maintenance 
of lysosomal Ca2+ homeostasis in cortical neurons under physiological conditions. Moreover, 
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we showed that also an increase in lysosomal pH can promote TRPML1 activation, and this 
observation is in agreement with the results reported by other research groups (Christensen 
K.A. et al., 2002; Lee J.H. et al., 2015).   
Since bafilomycin A1 disrupts lysosomal pH thus causing an impairment in cell 
homeostasis, we evaluated cell viability after the administration of this drug in order to rule out 
the possibility that it could affect neuronal survival during our functional experiments. To this 
aim, cells were incubated with 100 nM bafilomycin A1 for 2 minutes, 5 minutes and 1 hour 
under physiological conditions. At the end of treatments, cell viability was assessed in terms of 
mitochondrial function by MTT assay. Our data showed that the exposure to bafilomycin A1 
100 nM for 2 and 5 minutes did not affect cell viability during our experiments; however, longer 
exposure reduced neuronal survival of ~30% compared to control (Fig.16).  
 
 
 
 
 
 
Fig.16 - Bafilomycin A1 effects on cell viability in cortical neurons. Cell viability rate was determined 
by MTT assay on cortical neurons exposed to 100 nM bafilomycin A1 for 2 minutes, 5 minutes and 1 
hour. Cell viability of untreated controls was considered to be 100%.  
The experiment was repeated 3 times with similar results. 
* p<0.05 versus control. 
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4.3 The pharmacological modulation of TRPML1 or its knocking down 
modifies intracellular Ca2+ homeostasis in cortical neurons 
Recent experimental evidences demonstrated a tight coupling between lysosomes and 
the endoplasmic reticulum (ER), likely occurring at Ca2+ microdomains formed at membrane 
contact sites (MCSs) between the two organelles (Penny C.J. et al., 2015). Accordingly, it has 
been proposed that the close apposition between acidic Ca2+ stores and ER could generate 
relevant global Ca2+ signals within the cell (Patel S. and Docampo R., 2010). 
To verify the existence of a functional interplay between lysosomes and ER in cortical 
neurons, we performed single-cell Fura-2/AM microfluorimetry experiments under 
physiological conditions. We first measured cytosolic Ca2+ rise after the administration of the 
specific Ca2+ ionophore ionomycin (5 M), used to elicit Ca2+ release from all internal, non-
lysosomal Ca2+ stores, and in particular from ER. In neurons pre-treated for 1 hour with 
TRPML1 inhibitor trans-Ned19 (30 M) (hereafter referred to as Ned19) and in neurons 
transfected with the specific siRNA against TRPML1 mRNA, ionomycin induced a significant 
increase in cytosolic Ca2+ levels compared to control (Fig.17 A). These results suggest that the 
pharmacological inhibition of the channel or its knocking down promoted an increase in Ca2+ 
content within the ER and other non-lysosomal Ca2+ stores.   
Then, we measured ER Ca2+ content after the pharmacological or genetic knock down 
of TRPML1. To this aim we performed single-cell Fura-2/AM microfluorimetry experiments 
by using thapsigargin (Tg) in a Ca2+-free solution; this pharmacological tool, by blocking the 
ER Ca2+ ATPase SERCA, induced a slow release of Ca2+ from ER that we measured as [Ca2+]i 
increase in the cytosol. In our experiments, the pre-incubation with TRPML1 inhibitor Ned19 
for 1 hour or TRPMLI knocking down by siRNA significantly increased ER Ca2+ content 
(Fig.17 B). By contrast, the preliminary Ca2+ leak from lysosomes obtained by the pre-
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incubation with ML-SA1 for 1 hour determined a reduction in ER Ca2+ content of 
approximately 50% compared to control (Fig.17 C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.17 - Effect of the pharmacological modulation of TRPML1 or its knocking down on ER Ca2+ 
content in cortical neurons under physiological conditions. (A) Representative traces (top) and 
quantification (bottom) of the effect of Ned19 (30 M) and siTRPML1 on intracellular Ca2+ release 
from ER induced by ionomycin (5 M) in cortical neurons under physiological conditions. (B) 
Representative traces (top) and quantification (bottom) of the effect of Ned19 (30 M) and siTRPML1 
on ER Ca2+ content in cortical neurons. (C) Representative traces (top) and quantification (bottom) of 
the effect of ML-SA1 (10 M) on ER Ca2+ content in cortical neurons.  
All the experiments were repeated 3 times on almost 40 cells with similar results. 
* p<0.05 versus control. 
 
 
These results suggest that ER Ca2+ homeostasis is controlled by lysosomal Ca2+ via 
TRPML1 in cortical neurons under physiological conditions. 
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4.4 Lysosomes are coupled to endoplasmic reticulum (ER) in the handling 
of intracellular Ca2+ concentration 
Since in cortical neurons lysosomes and ER can communicate for the regulation of 
intracellular Ca2+ homeostasis under physiological conditions, we wondered about the 
molecular identity of the lysosomal and ER proteins promoting the interaction between the two 
organelles. In this respect, we hypothesized that Ca2+ exchanges between the two compartments 
could be controlled by the unique ER Ca2+ sensor actually known, namely STIM1 (stromal 
interaction molecule 1). STIM1 is a single transmembrane-spanning Ca2+-binding protein 
resident in the ER membrane, where it senses intraluminal Ca2+ levels (Spassova M. et al., 
2006). It is well known that when ER Ca2+ concentration decreases, STIM1 moves to plasma 
membrane where it oligomerizes and activates ORAI1 Ca2+ channel (also known as CRACM1, 
calcium release-activated calcium modulator 1), thus mediating Ca2+ influx within the cell. 
This mechanism is termed “store-operated Ca2+ entry” (SOCE) (Várnai P. et al., 2009). So, in 
order to verify whether STIM1 could mediate ER/lysosomes coupling, by means of co-
immunoprecipitation experiments we analyzed the possible interaction between STIM1 and 
TRPML1 under physiological conditions. The results obtained showed that under normoxia the 
two proteins co-immunoprecipitated in primary cortical neurons (Fig.18 A-B). To further 
investigate the interplay between lysosomes and ER, we also examined the possible interaction 
between TRPML1 and IP3R-3, one of the most abundant protein expressed at the level of ER 
membrane. Our co-immunoprecipitation experiments showed that the two proteins may interact 
(Fig.18 C), probably in order to promote Ca2+ exchanges between the two compartments. 
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Fig.18 - Lysosome/ER coupling is mediated by the interaction between TRPML1 and some ER 
membrane proteins under physiological conditions. (A-B) Lysates from cortical neurons were 
subjected to immunoprecipitation (IP) using anti-STIM1 or anti-TRPML1 antibody. The presence of 
TRPML1 or STIM1 was analyzed by Western blotting (WB). (C) Lysates from cortical neurons were 
subjected to immunoprecipitation (IP) using anti-IP3R-3 antibody. The presence of TRPML1 was 
analyzed by Western blotting (WB). 
All the experiments were repeated 3 times with similar results. 
 
 
Moreover, we also evaluated the co-localization between TRPML1 and STIM1 in our 
cells by means of immunocytochemical analysis. Our experiments revealed that the two 
proteins extensively co-localized in cortical neurons, in both soma and axons, under 
physiological conditions (Fig.19).  
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Fig.19 - Lysosome/ER coupling is mediated by STIM1/TRPML1 interaction under physiological 
conditions. STIM1 (STIM1-ATTO-550, red) and TRPML1 (green) immunosignals in cortical neurons 
under control conditions (a-h); nuclei were counterstained with Hoechst (blue). Higher magnifications 
of each frame illustrate STIM1/TRPML1 staining in the cell body (arrows, i-l) and along axons (arrows, 
m-o). Bar graph depicts the quantification of STIM1 and TRPML1 co-localization as Pearson’s 
coefficient value. Scale bars: 10 m (a-d), 5 m (e-h), and 2 m (i-o). The experiment was repeated 3 
times with similar results. 
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 On the basis of our results, we suggest that under physiological conditions STIM1 may 
interact with TRPML1 probably with the aim of allowing Ca2+ passage between the two 
organelles. This is an absolutely new evidence that will be corroborated by other experiments 
in the future. 
 
4.5 Biochemical characterization of TRPML1 expression in cortical 
neurons and cortical glial cells exposed to anoxic conditions   
Considering the existence of a physical and functional interplay between lysosomes and 
ER in cortical neurons under physiological conditions, we evaluated whether this 
interorganellar communication could be modified under hypoxic conditions reproducing brain 
ischemia. In order to obtain an in vitro model of the disease, primary cortical neurons were 
exposed to 3 hours of oxygen and glucose deprivation (OGD) followed by 24 hours of 
reoxygenation (Rx). In more detail, as already reported in the Materials and Methods section, 
neurons were incubated with a glucose-free medium and kept for 3 hours in a hypoxic chamber 
with a controlled atmosphere of N2/CO2 gases (95% N2, 5% CO2), to simulate the acute cerebral 
vessel occlusion that occurs in vivo. Cells were then exposed to normoxic, glucose-containing 
medium for 24 hours to reproduce the reperfusion phase occurring in pathological conditions 
(Scorziello A. et al., 2001).   
In our study, by means of Western blotting experiments, we analyzed the protein 
expression of TRPML1 in cortical neurons and in cortical glial cells exposed to 3 hours of OGD 
and 3 hours of OGD followed by 24 hours of reoxygenation. We observed that in cortical 
neurons TRPML1 expression levels were dramatically reduced during OGD; conversely, when 
OGD was followed by 24 hours of reoxygenation TRPML1 protein expression returned to 
control values (Fig.20 A). Interestingly, this phenomenon is neuron-specific, since anoxic 
conditions did not modulate the expression levels of the protein in cortical glial cells (Fig.20 
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B). Moreover, to demonstrate that anoxia did not induce a variation in the number of lysosomes 
within the cell, we also evaluated the expression of the lysosomal membrane protein LAMP2, 
which showed no significant modulation during anoxia in both cortical neurons and cortical 
glial cells (Fig.20 A-B).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.20 - Effect of OGD and OGD/Rx on TRPML1 protein expression in cortical neurons and in 
cortical glial cells. (A-B) Representative Western blotting (top) and quantification (bottom) of 
TRPML1 expression in cortical neurons (A) and in cortical glial cells (B) exposed to OGD and OGD/Rx.  
All the experiments were repeated 3 times with similar results. 
* p<0.05 versus control; ** p<0.05 versus OGD 3h. 
  
 
4.6 TRPML1 modification occurring during OGD triggers a dysfunction 
in lysosomal Ca2+ content  
To assess whether anoxic conditions could induce a dysregulation in lysosomal Ca2+ 
homeostasis, we measured lysosomal Ca2+ content in cortical neurons exposed to OGD and 
OGD/Rx by means of Fura-2/AM single-cell microfluorimetry technique. In our experiments, 
to elicit lysosomal Ca2+ release into the cytosol we used the TRPML1 agonist ML-SA1 (10 
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M). Our results showed that ML-SA1-induced lysosomal Ca2+ release significantly raised 
during OGD (Fig.21 A); in contrast, lysosomal Ca2+ efflux after ML-SA1 administration was 
strongly reduced when OGD was followed by 24 hours of reoxygenation (Fig.21 B). However, 
the pre-treatment for 10 minutes with the Ca2+ ionophore ionomycin, performed to elicit Ca2+ 
efflux from all intracellular non-lysosomal Ca2+ stores, and in particular from ER, caused a 
strong reduction in ML-SA1-induced lysosomal Ca2+ release during OGD (Fig.21 A), 
unmasking an experimental bias. Conversely, this pre-treatment failed to have the same effect 
on lysosomal Ca2+ release during OGD/Rx and under control conditions (Fig.21 A-B). Similar 
results were obtained when lysosomal Ca2+ release into the cytosol was promoted by using GPN 
(300 M), a lysosomotropic agent that induces the osmotic lysis of lysosomes (data not shown). 
 
 
 
 
 
 
 
Fig.21 - Lysosomal Ca2+ content is dysregulated in hypoxic neurons. (A-B) Quantification of the 
effect of ML-SA1-induced lysosomal Ca2+ release during OGD (A) and OGD/Rx (B), in the absence or 
presence of the Ca2+ ionophore ionomycin (A-B), in cortical neurons.  
All the experiments were repeated 3 times on almost 40 cells with similar results. 
* p<0.05 versus control; ** p<0.05 versus OGD and control. 
 
These results suggest that, during OGD, lysosomal Ca2+ content remained unmodified, 
while ER Ca2+ content increased, as already demonstrated by our research group in a previous 
paper (Sirabella R. et al., 2009). On the other hand, lysosomal Ca2+ strongly decreased during 
the reoxygenation phase, thus meaning that TRPML1 could be hyperfunctional during this 
phase, possibly due to an increased ROS production. That TRPML1 may be hyperactivated in 
a pathophysiological condition characterized by oxidative stress like anoxia is corroborated by 
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the recent findings by Zhang et al., who demonstrated that TRPML1 could be activated upon 
elevations in ROS levels, thus promoting an excessive Ca2+ release from lysosomes (Zhang X. 
et al., 2016).  
  
4.7 The pharmacological modulation of TRPML1 during the 
reoxygenation phase determines cell fate of anoxic cortical neurons  
Considering the biochemical and functional modifications of TRPML1 that we observed 
in cortical neurons exposed to anoxia and the strong reduction in cell viability occurring during 
OGD/Rx, we analyzed the effect of TRPML1 modulation under hypoxic conditions on neuronal 
survival. In this respect, we tested the effect of two pharmacological modulators of TRPML1 
activity during anoxia: its agonist ML-SA1, and its inhibitor Ned19. We also verified the effect 
of the chemical YM201636 (10 M), a potent inhibitor of the mammalian class III 
phosphatidylinositol phosphate kinase PIKfyve, which blocks the production of the endogenous 
activator of the channel, PI(3,5)P2 (Jefferies H.B. et al., 2008). Each drug was administered 
during OGD, at the onset of reoxygenation, or during both OGD and reoxygenation. In all the 
experiments, neuronal survival was evaluated by MTT assay at the end of the reoxygenation 
phase. 
Our MTT experiments demonstrated that the activation of the channel by ML-SA1 
failed to induce any effect on cell viability during anoxia, independently on the phase of 
administration (Fig.22 A). Similarly, no significant effect was observed when cells were treated 
with YM201636 during OGD or during the reoxygenation phase; however, when this drug was 
administered during both phases, it strongly affected neuronal survival compared to OGD/Rx 
(Fig.22 B). Moreover, at the cellular level, neurons treated with this chemical during anoxia 
displayed a vesiculation phenotype characterized by the presence of enlarged vacuolar 
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structures, thus suggesting a disruption in cell structure and function (data not shown). These 
data are consistent with an aspecific role of the phosphoinositide PI(3,5)P2 at neuronal level.  
In addition, no variation in cell viability was observed when cells were incubated with TRPML1 
inhibitor Ned19 during OGD, in which TRPML1 expression was downregulated; conversely, 
the administration of this drug during the reoxygenation phase was able to promote a strong 
increase in neuronal survival compared to OGD/Rx (Fig.22 C). Interestingly, this 
neuroprotective effect was similar to that observed in ischemic preconditioning 
(IPC+OGD/Rx), a well-known model to induce neuroprotection in anoxic neurons (Fig.22 C). 
Indeed, it has been already reported that in cortical neurons exposed to the preconditioning 
insult (30 minutes of OGD that precede OGD/Rx), the impairment in mitochondrial activity 
was partially rescued compared to neurons exposed to OGD/Rx alone (Scorziello A. et al., 
2007).  
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Fig.22 - Mitochondrial activity in cortical neurons exposed to anoxia and treated with three 
different drugs able to modulate TRPML1 function during OGD, during the reoxygenation, or 
during both phases. (A-C) Effect of ML-SA1 (10 M) (A), YM201636 (10 M) (B), and Ned19 (30 
M) (C) on cell viability in cortical neurons exposed to hypoxic conditions. 
Cell viability of untreated controls was considered to be 100%. 
All the experiments were repeated 3 times with similar results. 
* p<0.05 versus control; ** p<0.05 versus OGD/Rx. 
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These results suggest that the pharmacological inhibition of the channel at the beginning 
of the reoxygenation phase may exert a neuroprotective effect in cortical neurons exposed to 
anoxia. 
 
4.8 TRPML1 inhibition exerts a neuroprotective effect in hypoxic cortical 
neurons by modulating lysosomal Ca2+ homeostasis  
Since the pharmacological inhibition of TRPML1 during the reoxygenation phase 
strongly improved cell survival in hypoxic neurons, we verified the effect of Ned19 on 
lysosomal and ER Ca2+ coupling during OGD/Rx. We first studied whether the anoxic stimulus 
could hamper the physical coupling between the two organelles promoted by STIM1/TRPML1 
interaction. To this aim, we performed co-immunoprecipitation experiments followed by 
Western blotting analysis. Our results showed that the interaction between the two proteins 
observed under normoxia was maintained during OGD/Rx; interestingly, the pharmacological 
inhibition of TRPML1 during the reoxygenation phase did not block, but only slightly reduced, 
the physical coupling between lysosomes and ER (Fig.23 A-B).   
Then, we analyzed the effect of TRPML1 inhibition on lysosomal and ER Ca2+ 
homeostasis during anoxia. We found that the administration of this drug during the 
reoxygenation phase was able to revert the dysfunction of lysosomal Ca2+ homeostasis observed 
during OGD/Rx, by restoring a proper lysosomal Ca2+ content (Fig.23 C). We hypothesized 
that this effect is possibly due to the blockade of a hyperfunctional TRPML1 channel, which, 
due to the high ROS levels produced during the reoxygenation, could promote massive Ca2+ 
release from lysosomes. However, the pharmacological inhibition of TRPML1 failed to exert 
any effect on ER Ca2+ concentration during OGD/Rx (Fig.23 D).  
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Fig.23 - Effect of TRPML1 inhibition on lysosome/ER coupling during OGD/Rx. (A-B) Lysates 
from cortical neurons exposed to anoxia were subjected to immunoprecipitation (IP) using anti-STIM1 
or anti-TRPML1 antibodies. The presence of TRPML1 or STIM1 was analyzed by Western blotting 
(WB). The experiments were repeated 3 times with similar results. (C-D) Quantification of the effect of 
TRPML1 inhibition during the reoxygenation phase on lysosomal (C) and ER Ca2+ content (D) in 
cortical neurons exposed to OGD/Rx. All the experiments were repeated 3 times on almost 40 cells with 
similar results. 
For C and D, * p<0.05 versus control; ** p<0.05 versus OGD/Rx. 
 
Collectively, these data suggest that the Ca2+ coupling between lysosomes and ER is 
impaired during anoxia. In this respect, the lack of effect of Ned19 in restoring ER Ca2+ content 
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during the reoxygenation phase is possibly due to a disruption of lysosomes/ER membrane 
contact sites, or to an alteration in the functional coupling between the two organelles. These 
two putative events could both occur during the reoxygenation phase. However, our 
immunoprecipitation experiments revealed that a certain amount of interaction between the 
lysosomal channel TRPML1 and the ER Ca2+ sensor STIM1 was maintained in hypoxic 
neurons treated with TRPML1 inhibitor. On the basis of these evidences we suggest that the 
ineffectiveness of Ned19 on ER Ca2+ homeostasis during anoxia could be mainly linked to an 
impairment in the functional coupling occurring between lysosomes and ER.  
 
4.9 Effect of TRPML1 inhibition on ER stress and apoptotic cell death in 
cortical neurons exposed to OGD/Rx 
Since TRPML1 inhibition exerts a beneficial effect on neuronal survival and on 
lysosomal Ca2+ homeostasis in our in vitro model of brain ischemia, we tried to characterize 
the molecular mechanisms underlying Ned19-mediated neuroprotection.  
Several experimental evidences showed that ER stress and apoptotic cell death play a 
key role in the neurodegeneration associated to brain ischemia (Paschen W. et al., 2003; Shibata 
M. et al., 2003; Paschen W. and Mengersdorf T., 2005; Pallast S. et al., 2010). Thus, we verified 
whether the neuroprotective effect of Ned19 could be due to a reduction of the ER stress 
occurring during anoxia. To this aim, by means of Western blotting analysis, we evaluated the 
protein expression of GRP78 (also known as BiP), a molecular chaperone that activates the 
UPR (Unfolded Protein Response) in the presence of misfolded proteins in the lumen of ER 
(Malhotra J.D. and Kaufman R.J., 2007). Our results showed that GRP78 expression levels 
were increased after OGD/Rx, compared to control cells. Interestingly, the administration of 
Ned19 during the reoxygenation phase prevented the increase in GRP78 induced by anoxia 
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(Fig.24 A), thus suggesting that the pharmacological inhibition of TRPML1 protected cortical 
neurons exposed to hypoxic conditions by preventing ER stress.   
Moreover, we also evaluated the effect of TRPML1 inhibition on the expression of 
caspase 9, a pro-apoptotic marker known to be activated after severe and prolonged ER stress. 
Indeed, it has been reported that this protein, mainly involved in the intrinsic (mitochondria-
dependent) pathway of apoptosis, can also be activated by caspase 12, an ER-specific caspase 
that participates in apoptosis under ER stress (Morishima N. et al., 2002; Rao R.V. et al., 2002). 
Our results showed that OGD/Rx induced a strong increase in the expression levels of cleaved-
caspase 9, that was efficiently reduced by TRPML1 inhibition during the reoxygenation phase 
(Fig.24 B).  
   
 
 
 
 
 
 
 
 
 
 
Fig. 24 - Effect of TRPML1 inhibition on the expression of ER stress and apoptotic cell death 
markers during OGD/Rx. (A-B) Representative Western blotting (top) and quantification (bottom) of 
GRP78 (A) and cleaved-caspase 9 (B) expression in cortical neurons exposed to OGD/Rx and OGD/Rx 
(+Ned19).  
All the experiments were repeated 3 times with similar results. 
* p<0.05 versus control; ** p<0.05 versus OGD/Rx.  
 
Collectively, our results indicate that Ned19 is able to prevent the induction of ER stress 
and protects cortical neurons from apoptotic cell death induced by anoxia. 
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4.10 Effect of TRPML1 inhibition on the autophagic pathway in cortical 
neurons exposed to OGD/Rx 
The lysosomal Ca2+ channel TRPML1 is involved in the regulation of several Ca2+-
dependent functions within the cell and, in particular, it has been reported that Ca2+ released 
through this channel is responsible for the activation of autophagy (Medina D.L. et al., 2015; 
Zhang X. et al., 2016). So, starting from this evidence, by means of Western blotting 
experiments we studied the effect of the pharmacological inhibition of TRPML1 during anoxia 
on the expression of two proteins involved in the autophagic pathway: LC3-II, the 
autophagosome-associated form of LC3, and p62, an adaptor protein that recruits poly-
ubiquitylated substrates to autophagosomes. Our results showed that this drug was able to 
induce a significant accumulation of these two autophagic markers, compared to OGD/Rx 
(Fig.25 A-B).  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 25 - Effect of TRPML1 inhibition on the expression of autophagic markers during OGD/Rx.  
(A-B) Representative Western blotting (top) and quantification (bottom) of LC3-II (A) and p62 (B) 
expression in cortical neurons exposed to OGD/Rx and OGD/Rx (+Ned19).  
All the experiments were repeated 3 times with similar results. 
* p<0.05 versus control; ** p<0.05 versus OGD/Rx. 
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We postulated that this accumulation could be due to a block in the autophagic flux, 
rather than an increase in the process, induced by Ned19 during the reoxygenation. To confirm 
our hypothesis, the expression of LC3-II was evaluated under anoxia also after the 
administration of bafilomycin A1 during the reoxygenation phase; indeed, this drug has been 
reported to inhibit autophagy (Yamamoto A. et al., 1998; Mauvezin C. et al., 2015). We 
observed that during OGD/Rx bafilomycin A1 induced an accumulation of LC3-II (Fig.26) 
similar to that observed after the administration of Ned19. This result suggests that during 
OGD/Rx the accumulation of the autophagic markers is due to a block, rather than an activation, 
of the autophagic flux.   
 
 
 
 
 
 
 
 
 
 
Fig.26 - Effect of bafilomycin A1 on the expression of LC3-II during OGD/Rx. Representative 
Western blotting (top) and quantification (bottom) of LC3-II in cortical neurons exposed to OGD/Rx 
and OGD/Rx (+Bafilomycin A1).  
All the experiments were repeated 3 times with similar results. 
* p<0.05 versus control; ** p<0.05 versus OGD/Rx. 
 
Considering that the inhibition of the autophagic flux induced by bafilomycin A1 is due 
to a block in the fusion of autophagosomes with lysosomes (Yamamoto A. et al., 1998; 
Mauvezin C. et al., 2015), we hypothesized that Ned19 could inhibit autophagy through the 
same mechanism in our cellular model.   
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In order to analyze the block in the autophagic flux, we performed immunoprecipitation 
experiments in which we evaluated the possible interaction between the autophagosomal 
membrane protein LC3-II and the lysosomal membrane protein LAMP1. In order to verify that 
this technique could be suitable for our purpose, as positive control, we tested the effect of 
bafilomycin A1 on the interaction between the two proteins under physiological conditions. 
The results obtained demonstrated that under normoxia LAMP1 and LC3-II physically 
interacted; interestingly, the incubation for 1 hour with 100 nM bafilomycin A1 was able to 
reduce the interaction between the two proteins (Fig.27), thus confirming that this drug 
interferes with autophagosomes/lysosomes fusion. 
 
 
 
 
 
Fig.27 - Effect of bafilomycin A1 on the interaction between lysosomal and autophagosomal 
proteins in cortical neurons under physiological conditions. Lysates from cortical neurons under 
physiological conditions were subjected to immunoprecipitation (IP) using anti-LAMP1 antibody. The 
presence of LC3-II was analyzed by Western blotting (WB). 
The experiment was repeated 3 times with similar results. 
 
Then, to verify the possibility that Ned19 could cause a similar defect in the fusion 
between autophagosomes and lysosomes, the interaction between LAMP1 and LC3-II was also 
evaluated after the administration of the pharmacological inhibitor of TRPML1 under both 
physiological and hypoxic conditions. We observed that in cortical neurons exposed to 
normoxia the incubation with Ned19 for 1 hour strongly decreased the co-immunoprecipitation 
of the two proteins. This interaction, preserved in neurons exposed to OGD/Rx, was also 
reduced by Ned19 in anoxic neurons (Fig.28). 
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Fig.28 - Effect of Ned19 on the interaction between the lysosomal and autophagosomal proteins in 
cortical neurons under physiological conditions and in neurons exposed to anoxia. Lysates from 
cortical neurons exposed to anoxia were subjected to immunoprecipitation (IP) using anti-LAMP1 
antibody. The presence of LC3-II was analyzed by Western blotting (WB). 
The experiment was repeated 3 times with similar results. 
 
 
Altogether, our results suggest that the neuroprotective effect of Ned19 in anoxic 
neurons was due to a blockade in the autophagic flux caused by an impaired fusion between 
autophagosomes and lysosomes. We hypothesize that this blockade could improve neuronal 
status by reducing the elimination of intracellular organelles (such as mitochondria) and 
components that are partially damaged, but still functional. Indeed, the degradation of these 
cellular constituents could represent a detrimental event for neuronal survival, already 
compromised during OGD/Rx. Moreover, by destroying partially impaired mitochondria, 
autophagy could also reduce the number of these compartments, and so produce a secondary 
energy failure in post-ischemic neurons. 
 
4.11 The pharmacological inhibition of TRPML1 exerts a neuroprotective 
effect on ischemic damage in rats subjected to transient focal ischemia 
Considering the neuroprotective effect of TRPML1 inhibition in anoxic neurons, we 
tested Ned19 in an in vivo rat model of transient cerebral ischemia (tMCAO), by evaluating the 
effect of this drug on both brain infarct volume and neurological deficits induced by brain 
ischemia. Interestingly, we observed that Ned19, intracerebroventricularly (icv) infused at the 
onset of reperfusion in ischemic rats, significantly reduced the extent of the ischemic damage 
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of ~40% compared to rats subjected to tMCAO and treated with vehicle (Fig.29 A). 
Furthermore, the reduction in the ischemic volume induced by Ned19 was accompanied by a 
marked improvement in general and focal neurological scores of animals subjected to cerebral 
ischemia (Fig.29 B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.29 - Quantification of infarct volume after 100 minutes of tMCAO and administration of 
Ned19 coupled with performance of general and focal neurological deficits after TRPML1 
inhibition in ischemic rats. (A) Effect of Ned19 on infarct volume of rats subjected to 100 minutes of 
tMCAO compared to ischemic rats treated with vehicle, all analyzed after 24 hours. On the top side 
representative coronal brain slices indicating the extension of the infarct area are reported. (B) Effect of 
Ned19 on general and focal neurological scores (horizontal line indicates the mean neurological score).  
For A and B: 
n = 5-6 animals per group. 
* p<0.05 versus tMCAO + vehicle.  
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Then, we also tested the effect of Ned19 infusion at different time points after the onset 
of reperfusion (3 hours, 6 hours, 12 hours, and 24 hours). Unfortunately, the results obtained 
indicated that TRPML1 inhibition at these time points failed to induce any significant reduction 
in the ischemic volume or amelioration in general and focal deficits in rats subjected to tMCAO 
(data not shown). This could be due to the coexistence of other mechanisms occurring during 
the reperfusion phase. 
In addition, by means of Western blotting experiments, we evaluated the effect of Ned19 
administration at the onset of reperfusion on the expression of the autophagic markers p62 and 
LC3-II in the ipsilateral cortex of rats subjected to brain ischemia. We observed that in this 
cerebral tissue affected by the ischemic insult, the pharmacological inhibition of TRPML1 was 
able to induce an increase of both the proteins (Fig.30), as it occurs in our in vitro model of the 
disease.    
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 30 - Effect of TRPML1 inhibition on the expression of autophagic markers in the ipsilateral 
cortex of ischemic rats. Representative Western blotting and quantification of p62 and LC3-II 
expression in the ipsilateral cortex of sham-operated (controls), ischemic (tMCAO), and Ned19-treated 
ischemic (tMCAO+Ned19) rats.  
n = 5 animals per group. 
* p<0.05 versus sham-operated group; ** p<0.05 versus tMCAO. 
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Moreover, we also analyzed the expression of p62 and LC3-II in the ipsilateral cortex 
of rats subjected to tMCAO and icv infused with Ned19 at three hours after the onset of 
reperfusion. As expected, the modulation in the expression of these two autophagic markers 
was not statistically significant (data not shown). Indeed, the infusion of the drug at this time 
point did not induce any significant reduction in the ischemic brain volume nor any amelioration 
in general and focal deficits in ischemic rats. 
Collectively, our in vivo results demonstrate that the pharmacological inhibition of 
TRPML1 at the onset of the reperfusion is able to reduce the ischemic damage induced by 
tMCAO and suggest that the neuroprotective effect of Ned19 during the reperfusion phase may 
be linked to a block in the autophagy flux.  
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CONCLUSIONS 
A physical and functional coupling between the endoplasmic reticulum (ER) and 
lysosomes has been recently reported to occur in different cell types under physiological 
conditions (Kilpatrick B.S. et al., 2013; Kilpatrick B.S. et al., 2016b; Aston D. et al., 2017). 
Indeed, lysosomes, that participate in the regulation of intracellular Ca2+ homeostasis under 
both physiological and pathological conditions, can communicate with the ER for the handling 
of intracellular Ca2+ concentration (Patel S. and Docampo R., 2010; Morgan A.J. et al., 2011). 
A recent study highlighted the involvement of TRPML1 in the communication between the two 
organelles in human fibroblasts (Kilpatrick B.S. et al., 2016b). Despite being a non-selective 
cation channel, TRPML1 is the main Ca2+-extruding system localized to lysosomal membrane. 
Loss-of-function mutations in mcoln1, the gene encoding for TRPML1, cause mucolipidosis 
type IV (MLIV), a devastating lysosomal storage disorder characterized by neurodegeneration 
(Bargal R. et al., 2000; Bassi T.M. et al., 2000; Sun M. et al., 2000). So far, there is no evidence 
in literature about the possible contribution of this channel in the maintenance of intracellular 
Ca2+ homeostasis in the neurodegeneration associated to brain ischemia. However, it is well-
known that dysfunctions in the ER play a key role in the neurodegenerative mechanisms 
underlying this neurological disorder (Paschen W. et al., 2003; Shibata M. et al., 2003; Paschen 
W. and Mengersdorf T., 2005; Sirabella et al., 2009; Pallast S. et al., 2010).   
So far, many drugs have been tested for the treatment of acute ischemic stroke; however, 
none of them has been proven to be effective. At present, the only effective drug approved by 
the FDA and EMA for the treatment of brain ischemia is the recombinant tPA (tissue 
plasminogen activator), but its administration is characterized by some limitations, including 
the appearance of some adverse effects (Donnan G.A. et al., 2008; Brouns R. and De Deyn P.P., 
2009; Haelewyn B. et al., 2010). Thus, the identification of novel molecular mechanisms 
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underlying this widespread neurological disease could help researchers in the development of 
new and more efficacious drugs for its pharmacological treatment.  
My PhD thesis is mainly focused on the study of a novel role for TRPML1 in the 
regulation of intracellular Ca2+ homeostasis during brain ischemia. Indeed, we investigated for 
the first time the possible contribution of this channel in the functional coupling between 
lysosomes and ER for intracellular Ca2+ handing in some experimental models of the disease. 
Briefly, in the first part of my PhD work, TRPML1 involvement in lysosomes/ER Ca2+ coupling 
was evaluated in rat primary cortical neurons under physiological conditions. Our results 
showed that the pharmacological or genetic modulation of the channel was able to modify ER 
Ca2+ content, thus suggesting the existence of an interplay between the two Ca2+ stores at 
neuronal level controlled by TRPML1. In the second part of my thesis, considering the 
dysfunction of ER Ca2+ homeostasis occurring during brain ischemia, we verified whether the 
functional crosstalk between lysosomes and ER observed under physiological conditions could 
be impaired under pathological conditions. In particular, we showed that in our in vitro model 
of the disease, represented by cortical neurons exposed to oxygen and glucose deprivation 
(OGD) followed by reoxygenation (Rx), the protein expression of the channel was strongly 
modulated, with a significant downregulation during OGD and a return to the control levels 
after the reoxygenation. In addition, the anoxic stimulus not only led to neuronal death, but also 
strongly impaired the function of the channel, thus resulting in a disruption of the functional 
coupling between lysosomes and ER during anoxia. Interestingly, the results presented in this 
thesis work demonstrated that the pharmacological inhibition of TRPML1 by means of Ned19 
during the reoxygenation phase exerted a neuroprotective effect in anoxic neurons by restoring 
lysosomal Ca2+ content, by preventing ER stress and apoptotic cell death, and by blocking the 
autophagic flux. Interestingly, in an in vivo model of brain ischemia represented by rats 
subjected to the transient middle cerebral artery occlusion (tMCAO), this drug, 
intracerebroventricularly infused at the onset of reperfusion, was able to improve the 
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neurological deficits and to reduce the extent of brain damage following the injury by blocking 
the hyperactive autophagic flux. Unfortunately, the administration of Ned19 at different time 
points after the onset of reperfusion, performed to establish a therapeutic time window for this 
drug, failed to exert any neuroprotective effect in ischemic rats. This failure could be due to the 
activation of other concomitant mechanisms during the reperfusion phase that will be further 
investigated in the future.   
In conclusion, my PhD thesis highlights the detrimental role of TRPML1 dysfunction 
in the neurodegeneration associated to brain ischemia and identifies a novel potential 
therapeutic target that could be pharmacologically modulated, together with other relevant 
mechanisms, to promote neuroprotection. Furthermore, my study contributed to identify the 
exact time window in which the autophagic flux could be considered hyperactive and, therefore, 
potentially druggable.  
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